ALT5 Sigma (ALTS) 10-Q19 Aug 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 29, 2024	Aug. 15, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 29, 2024
Document Transition Report	false
Entity File Number	0-19621
Entity Registrant Name	ALT5 Sigma Corporation
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	41-1454591
Entity Address, Address Line One	325 E. Warm Springs Road
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89119
City Area Code	702
Local Phone Number	997-5968
Entity Information, Former Legal or Registered Name	JanOne Inc.
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	ALTS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,769,015
Entity Central Index Key	0000862861
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Assets
Cash and cash equivalents	$ 5,764	$ 5
Trade and other receivables, net	984	266
Digital assets receivable	22,477	0
Prepaid expenses and other current assets	1,660	75
Total current assets	30,885	346
Property and equipment, net	1,170	0
Right of use assets	186	0
Marketable securities	434	286
Deposits and other assets	0	9
Total intangible assets	34,996	17,846
Goodwill	7,724	0
Total assets	75,395	18,487
Liabilities:
Accounts payable	2,937	2,272
Accrued liabilities	2,438	3,633
Digital assets payable	28,241	0
Due to Soin	2,900	0
Convertible debentures	1,686	0
Operating lease liabilities	59	0
Total current liabilities	42,511	5,905
Deferred income taxes, net	1,587	639
Notes payable	3,868	0
Operating lease liabilities	127	0
Other noncurrent liabilities	0	34
Total liabilities	48,609	7,285
Commitments and contingencies (Note 16)
Mezzanine equity
Convertible preferred stock, series S - par value $0.001 per share, 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at June 29, 2024 and December 30, 2023, respectively	3,900
Stockholders' equity:
Common stock, par value $0.001 per share, 200,000,000 shares authorized, 12,589,015 and 4,957,647 shares issued and outstanding at June 29, 2024 and at December 30, 2023, respectively	7	3
Accumulated other comprehensive deficit	(807)	0
Additional paid-in capital	59,374	47,323
Accumulated deficit	(52,189)	(50,634)
Total stockholders' equity (deficit)	22,930	(3,308)
Total liabilities and stockholders' equity	75,395	18,487
Series S
Mezzanine equity
Convertible preferred stock, series S - par value $0.001 per share, 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at June 29, 2024 and December 30, 2023, respectively	3,856	14,510
Stockholders' equity:
Preferred stock, value	7,993	0
Series A-1 Preferred
Stockholders' equity:
Preferred stock, value	0	0
Series B
Stockholders' equity:
Preferred stock, value	8,552	0
Series M
Stockholders' equity:
Preferred stock, value	0	0
Nonrelated Party
Liabilities:
Notes payable	3,244	0
Related Party
Liabilities:
Notes payable	1,006	0
Related party notes payable	$ 516	$ 707

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 29, 2024	Dec. 30, 2023
Common Stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, issued shares (in shares)	12,589,015	4,957,647
Common stock, outstanding shares (in shares)	12,589,015	4,957,647
Series S
Convertible preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (in shares)	200,000	200,000
Convertible preferred stock, shares outstanding (in shares)	100,000	100,000
Convertible preferred stock, shares issued (in shares)	100,000	100,000
Series A-1 Preferred
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	69,980	193,730
Preferred stock, outstanding shares (in shares)	69,980	193,730
Series B
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	34,250	34,250
Preferred stock, shares issued (in shares)	34,207	0
Preferred stock, outstanding shares (in shares)	34,207	0
Series M
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	3,200	3,200
Preferred stock, shares issued (in shares)	3,200	0
Preferred stock, outstanding shares (in shares)	3,200	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Statement of Comprehensive Income [Abstract]
Revenues	$ 2,169	$ 0	$ 2,169	$ 0
Cost of revenues	1,071	0	1,071	0
Gross profit	1,098	0	1,098	0
Operating expenses:
Selling, general and administrative expenses	4,014	1,060	5,820	2,159
Operating loss	(2,916)	(1,060)	(4,722)	(2,159)
Other income (expense):
Interest income (expense), net	4	365	(248)	840
Unrealized loss on marketable securities	(180)	0	(370)	(247)
Unrealized gain on exchange transactions	461	0	461	0
Realized gain on exchange transactions	240	0	240	0
Other income, net	129	757	158	739
Total other income, net	654	1,122	241	1,332
Income (loss) from continuing operations before provision for income taxes	(2,262)	62	(4,481)	(827)
Income tax benefit	(2,851)	(17)	(2,926)	(244)
Net income (loss) from continuing operations	589	79	(1,555)	(583)
Gain from discontinued operations	0	1	0	13,976
Income tax provision (benefit) for discontinued operations	0	(43)	0	3,186
Net income from discontinued operations	0	44	0	10,790
Net income (loss)	$ 589	$ 123	$ (1,555)	$ 10,207
Net income (loss) per share:
Net income (loss) per share from continuing operations, basic (in usd per share)	$ 0.07	$ 0.02	$ (0.18)	$ (0.17)
Net income (loss) per share from continuing operations, diluted (in usd per share)	0.07	0.02	(0.18)	(0.17)
Net income per share from discontinued operations, basic (in usd per share)	0	0.01	0	3.14
Net income per share from discontinued operations, diluted (in usd per share)	0	0.01	0	3.14
Net income per shares, basic (in usd per share)	0.07	0.03	(0.18)	2.97
Net income per share, diluted (in usd per share)	$ 0.07	$ 0.03	$ (0.18)	$ 2.97
Weighted average common shares outstanding:
Basic (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Diluted (in shares)	8,404,102	3,665,887	8,426,349	3,432,374

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
OPERATING ACTIVITIES:
Net income loss from continuing operations	$ (1,555)	$ (583)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,300	727
Stock based compensation expense	1,507	12
Related party notes issued for shared services	600	0
Accretion of note receivable discount	0	(518)
Unrealized gain on marketable securities	370	247
Unrealized gain on digital assets	(461)	0
Change in deferred tax liability	(2,927)	0
Changes in assets and liabilities:
Accounts receivable, net of acquisitions and dispositions	1,730	342
Digital assets receivable	(13,280)	0
Prepaid expenses and other current assets, net of dispositions	262	292
Digital assets payable	11,478	0
Accounts payable and accrued expenses, net of dispositions	503	(529)
Other Assets	9	1
Operating cash flows provided by discontinued operations	0	2,320
Net cash (used in) provided by operating activities	(464)	2,311
INVESTING ACTIVITIES:
Cash acquired in Alt5 Subsidiary acquisition	5,853	0
Investing cash flows used in discontinued operations	0	(156)
Net cash provided by (used in) investing activities	5,853	(156)
FINANCING ACTIVITIES:
Proceeds from equity financing, net	851	368
Proceeds from related parties	577	0
Payments on notes payable	(251)	(274)
Financing cash flows from discontinued operations	0	(2,212)
Net cash provided by (used in) financing activities	1,177	(2,118)
Effect of changes in exchange rate on cash and cash equivalents	(807)	17
INCREASE IN CASH AND CASH EQUIVALENTS	5,759	54
CASH AND CASH EQUIVALENTS, beginning of period	5	115
LESS CASH OF DISCONTINUED OPERATIONS, end of period	0	0
CASH AND CASH EQUIVALENTS, end of period	5,764	169
Supplemental cash flow disclosures:
Interest paid	0	118
Income taxes paid	0	0
Noncash recognition of new leases	186	0
Other Significant Noncash Transactions [Line Items]
Notes payable converted to common stock	122	0
Common stock issued for property and equipment	1,170	0
Stock issued for the acquisition of Alt5 Subsidiary
Other Significant Noncash Transactions [Line Items]
Stock Issued	16,000	0
Common stock issued for consulting services
Other Significant Noncash Transactions [Line Items]
Stock Issued	853	0
Common stock issued liability obligations
Other Significant Noncash Transactions [Line Items]
Stock Issued	$ 367	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Deficit	Series A-1 Preferred	Series A-1 Preferred Preferred Stock	Series S-1 Preferred Preferred Stock	Series B Preferred Preferred Stock	Series M Preferred Preferred Stock
Beginning balance (in shares) at Dec. 31, 2022							222,588	100,000
Beginning balance at Dec. 31, 2022	$ 2,307	$ 2	$ 45,748	$ (42,822)	$ (621)		$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2022		3,150,230
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	8		8
Common stock issued for equity financing (in shares)		361,000
Common stock issued for equity financing	369	$ 1	368
Series A-1 Preferred converted for legal settlement (in shares)		103,707					(5,185)
Series A-1 Preferred converted for legal settlement	170		170
Other comprehensive income	621				621
Net income	10,085			10,085
Ending balance (in shares) at Apr. 01, 2023							217,403	100,000
Ending balance at Apr. 01, 2023	13,560	$ 3	46,294	(32,737)	0		$ 0	$ 0
Ending balance (in shares) at Apr. 01, 2023		3,614,937
Beginning balance (in shares) at Dec. 31, 2022							222,588	100,000
Beginning balance at Dec. 31, 2022	2,307	$ 2	45,748	(42,822)	(621)		$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2022		3,150,230
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	10,207
Ending balance (in shares) at Jul. 01, 2023							217,403	100,000
Ending balance at Jul. 01, 2023	13,688	$ 3	46,299	(32,614)	0		$ 0	$ 0
Ending balance (in shares) at Jul. 01, 2023		3,614,937
Beginning balance (in shares) at Apr. 01, 2023							217,403	100,000
Beginning balance at Apr. 01, 2023	13,560	$ 3	46,294	(32,737)	0		$ 0	$ 0
Beginning balance (in shares) at Apr. 01, 2023		3,614,937
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	$ 5		5
Common stock issued for consulting agreement (in shares)	0
Net income	$ 123			123
Ending balance (in shares) at Jul. 01, 2023							217,403	100,000
Ending balance at Jul. 01, 2023	13,688	$ 3	46,299	(32,614)	0		$ 0	$ 0
Ending balance (in shares) at Jul. 01, 2023		3,614,937
Beginning balance (in shares) at Dec. 30, 2023						193,730	193,730	100,000	0	0
Beginning balance at Dec. 30, 2023	$ (3,308)	$ 3	47,323	(50,634)	0		$ 0	$ 0	$ 0	$ 0
Beginning balance (in shares) at Dec. 30, 2023	4,957,647	4,957,647
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	$ 345		345
Reclassification of Series S stock to liability	(339)		(339)
Reclassification of Series S stock to permanent equity	7,993
Common stock issued for equity financing (in shares)		884,880
Common stock issued for equity financing	627	$ 1	626
Common stock issued for consulting agreement (in shares)		600,000
Common stock issued for consulting agreement	367	$ 1	366
Common stock issued for consulting agreement (in shares)		200,000
Common stock issued for consulting agreement	232		232
Common stock issued for RSU's granted (in shares)		908,852
Net income	(2,144)			(2,144)
Ending balance (in shares) at Mar. 30, 2024							193,730	100,000	0	0
Ending balance at Mar. 30, 2024	3,773	$ 5	48,553	(52,778)	0		$ 0	$ 0	$ 0	$ 0
Ending balance (in shares) at Mar. 30, 2024		7,551,379
Beginning balance (in shares) at Dec. 30, 2023						193,730	193,730	100,000	0	0
Beginning balance at Dec. 30, 2023	$ (3,308)	$ 3	47,323	(50,634)	0		$ 0	$ 0	$ 0	$ 0
Beginning balance (in shares) at Dec. 30, 2023	4,957,647	4,957,647
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification of Series S stock to permanent equity	$ 8,000
Series A-1 Preferred converted for legal settlement (in shares)						123,750
Net income	(1,555)
Ending balance (in shares) at Jun. 29, 2024						69,980	69,980	100,000	34,207	3,200
Ending balance at Jun. 29, 2024	$ 22,930	$ 7	59,374	(52,189)	(807)		$ 0	$ 0	$ 8,552	$ 0
Ending balance (in shares) at Jun. 29, 2024	12,589,015	12,589,015
Beginning balance (in shares) at Mar. 30, 2024							193,730	100,000	0	0
Beginning balance at Mar. 30, 2024	$ 3,773	$ 5	48,553	(52,778)	0		$ 0	$ 0	$ 0	$ 0
Beginning balance (in shares) at Mar. 30, 2024		7,551,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation (in shares)		295,000
Share based compensation	1,161		1,161
Stock issued during period, shares, acquisitions		1,799,115							34,207	3,200
Stock issued during period, value, acquisitions	7,448	$ 1	7,447						$ 8,552
Conversion of note receivable to common stock (in shares)		200,000
Conversion of note receivable to common stock	122		122
Common stock issued for equity financing (in shares)		120,598
Common stock issued for equity financing	$ 342		342
Common stock issued for consulting agreement (in shares)	0	197,923
Common stock issued for consulting agreement	$ 580	$ 1	579
Series A-1 Preferred converted for legal settlement (in shares)		2,125,000					(123,750)
Common stock issued for property and equipment (in shares)		300,000
Common stock issued for property and equipment	1,170		1,170
Foreign currency adjustment	(807)				(807)
Net income	589			589
Ending balance (in shares) at Jun. 29, 2024						69,980	69,980	100,000	34,207	3,200
Ending balance at Jun. 29, 2024	$ 22,930	$ 7	$ 59,374	$ (52,189)	$ (807)		$ 0	$ 0	$ 8,552	$ 0
Ending balance (in shares) at Jun. 29, 2024	12,589,015	12,589,015

Background

Background	6 Months Ended
Background	Jun. 29, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	Background The accompanying consolidated financial statements include the accounts of ALT5 Sigma Corporation, a Nevada corporation, and its subsidiaries (collectively, the “Company” or “ALT5”). Effective July 15, 2024, the Company changed its corporate name from “JanOne Inc.” to “ALT5 Sigma Corporation,” and also changed its Nasdaq common stock ticker symbol from “JAN” to “ALTS”. The corporate name change was effected through a parent/subsidiary short-form merger of ALT5 Sigma Corporation, the Company's wholly-owned Nevada subsidiary formed solely for the purpose of effectuating the name change), whereby it merged with and into the Company, with the Company being the surviving entity, albeit with its new name. The Company had three operating segments – Biotechnology, Fintech, and Recycling. In connection with the sale of ARCA Recycling, Inc. (“ARCA Recycling”), the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements. Biotechnology During September 2019, ALT5 Sigma Corporation, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone, (“JAN123”). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales. Fintech On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets (see Note 3). Recycling ARCA Recycling was the Company’s Recycling segment and provides turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Canada Inc. (“ARCA Canada”) provides turnkey recycling services for electric utility energy efficiency programs in Canada. Customer Connexx, LLC (“Connexx”) provides call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. The Company’s Board of Directors unanimously approved the Purchase Agreement and the Disposition Transaction. In connection with the disposition of ARCA Recycling, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements (see Note 4). The Company reports on a 52- or 53-week fiscal year. The Company’s 2023 fiscal year (“2023”) ended on December 30, 2023, and the current fiscal year (“2024”) will end on December 28, 2024. Going concern The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company’s ability to do so. The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $1.6 million for the 26 weeks ended June 29, 2024. Additionally, as of June 29, 2024, the Company has total current assets of approximately $30.9 million and total current liabilities of approximately $42.5 million resulting in a net negative working capital of approximately $11.6 million. Cash used in operations from continuing operations was approximately $464,000. Additionally, stockholders’ equity, as of June 29, 2024, is approximately $22.9 million. The Company intends to raise funds to support future development of JAN 123 and JAN 101 and through a combination of cash flows derived from its acquisition of ALT5 (see Note 3), capital raises, and/or structured arrangements. However, the success of such funding cannot be assured.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 29, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies B asis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 30, 2023. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Reclassifications Certain amounts in the prior period have been reclassified to conform to the current period presentation. These reclassifications have no material effect on the reported financial results. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, the Series B and Series M preferred stock issued in the transaction, pursuant to which the Company acquired the ALT5 Subsidiary, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets. Financial Instruments Financial instruments consist primarily of cash equivalents, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. Digital Assets and other Receivables Digital assets and other receivables are the Company’s digital assets and its customer prepayments in the form of digital assets. The Company holds all digital assets in secure non-custodial wallets through the wallet services from Fireblocks. As of June 29, 2024, the outstanding balance of digital assets and other receivables was approximately $22.5 million. Digital Assets and other Payables Digital assets and other payables are liabilities that represent the Company’s obligation to deliver the settlement of transactions in the form of digital assets and or cash. The Company safeguards these digital assets and cash for customers and is obligated to safeguard them from loss, theft, or other misuse. The Company recognizes digital assets and other payables, on initial recognition and at each reporting date, at fair value of the digital assets. Any loss, theft, or other misuse would impact the measurement of digital assets and other payables. As of June 29, 2024, the outstanding balance of digital assets and other payables was approximately $28.2 million. Revenue Recognition Revenue recognition applies to the Company's Fintech segment only, as the Company's Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements: 1. Executed contracts with the Company’s customers that it believes are legally enforceable; 2. Identification of performance obligations in the respective contract; 3. Determination of the transaction price for each performance obligation in the respective contract; 4. Allocation of the transaction price to each performance obligation; and 5. Recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to each of the Company’s revenue category, is summarized below: 1. Product sales – revenue is recognized at the time of sale of equipment to the customer. 2. Service sales – revenue is recognized based on when the service has been provided to the customer. The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis. The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets. The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided. The Company charges a fee at the transaction level. The transaction price, represented by the trading fee, is calculated based on volume and varies depending on payment type and the value of the transaction. Digital asset purchases or sale transactions executed by a customer on the Company’s platform is based on tiered pricing that is driven primarily by transaction volume processed for a specific historical period. The Company has concluded that this volume-based pricing approach does not constitute a future material right since the discount is within a range typically offered to a class of customers with similar volume. The transaction fee is collected from the customer at the time the transaction is executed. In certain instances, the transaction fee can be collected in digital assets, with revenue measured based on the amount of digital assets received and the fair value of the digital assets at the time of the transaction. The Company also marks up or down the digital asset prices and earns revenue from the spread between the buying and selling price. The Company also earns a fee from transfers of currencies and or digital assets. The transfer fees are nominal and are set to offset the fees associated with banking and or blockchain mining fees. Stock-Based Compensation The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period. Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Mergers and Acquisitions

Mergers and Acquisitions	6 Months Ended
Mergers and Acquisitions	Jun. 29, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Mergers and Acquisitions	Mergers and Acquisitions ALT5 On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets. As consideration under the acquisition, the Company issued 1,799,100 shares of its common stock to the legacy equity holders of the capital stock of ALT5 Subsidiary. Those shares represented approximately 19.9% of the Company's then-issued and outstanding shares of common stock. Each of the shares of the Company's newly-issued common stock was valued at $4.14, which was the Nasdaq NOCP on Thursday, May 9, 2024, the day immediately prior to the date on which the agreement was executed. The Company also issued 34,207 shares of its newly-designated Series B Preferred Stock (the “Series B Stock”) to the legacy equity holders of the capital stock of ALT5. In connection with the closing of the acquisition of ALT5 Subsidiary, the Company also issued 3,200 shares of its newly-designated Series M Preferred Stock (the “Series M Stock”) to two entities that acted as finders for the transaction. The fair value of the purchase price components outlined above was $16.0 million due to fair value adjustments for the shares of Series B and Series M Preferred Stock, as detailed below (in $000’s): Common stock $ 7,448 Series B preferred stock 8,552 Total purchase price $ 16,000 Under the preliminary purchase price allocation, the Company recognized goodwill of approximately $3.8 million, which is calculated as the excess of both the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired. The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of May 10, 2024, as calculated by an independent third-party firm. Because the transaction was considered a stock purchase for tax purposes, none of the goodwill arising from the acquisition will deductible for tax purposes. During the thirteen weeks ended June 29, 2024, the Company recorded a noncash fair value adjustment related to deferred tax liabilities in the aggregate amount of approximately $3.9 million, which was recorded to goodwill. The table below outlines the purchase price allocation of the purchase for ALT5 Subsidiary to the acquired identifiable assets, liabilities assumed and goodwill (in $000’s): Total purchase price $ 16,000 Accounts payable 267 Digital assets payable 16,763 Debt 7,613 Total liabilities assumed 24,643 Total consideration 40,643 Cash 5,853 Accounts receivable 2,917 Digital assets receivable 9,082 Intangible assets Customer relationships $ 13,925 Trade names 2,675 Developed technology 1,850 Subtotal intangible assets 18,450 Other 492 Total assets acquired 36,794 Total goodwill $ 3,849 Proforma Information The table below presents selected proforma information for the Company for the thirteen and twenty-six week periods ended June 29, 2024, assuming that the acquisition had occurred on January 1, 2023 (the beginning of the Company’s 2023 fiscal year), pursuant to ASC 805-10-50 (in $000's). This proforma information does not purport to represent what the actual results of operations of the Company would have been had the acquisition occurred on that date, nor does it purport to predict the results of operations for future periods. As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 13 weeks ended June 29, 2024 ALT5 Subsidiary Unaudited 13 weeks ended June 29, 2024 Adjustments(1) ALT5 Sigma Corporation for the 13 weeks ended June 29, 2024 Net revenue $ 2,169 $ 693 $ 2,862 Net income $ 589 $ 206 $ (269) $ 526 Earnings per basic common share $ 0.07 $ 0.06 Earnings per basic diluted share $ 0.07 $ 0.06 As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 13 weeks ended July 1, 2023 ALT5 Subsidiary Unaudited 13 weeks ended July 1, 2023 Adjustments(1) ALT5 Sigma Corporation for the 13 weeks ended July 1, 2023 Net revenue $ — $ 2,021 $ 2,021 Net income $ 123 $ 1,157 $ (537) $ 743 Earnings per basic common share $ 0.03 $ 0.20 Earnings per basic diluted share $ 0.03 $ 0.20 As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 26 weeks ended June 29, 2024 ALT5 Subsidiary Unaudited 26 weeks ended June 29, 2024 Adjustments(1) ALT5 Sigma Corporation for the 26 weeks ended June 29, 2024 Net revenue $ 2,169 $ 2,918 $ 5,087 Net income $ (1,555) $ 71 $ (806) $ (2,290) Earnings per basic common share $ (0.18) $ (0.27) Earnings per basic diluted share $ (0.18) $ (0.27) As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 26 weeks ended July 1, 2023 ALT5 Subsidiary Unaudited 26 weeks ended July 1, 2023 Adjustments(1) ALT5 Sigma Corporation for the 26 weeks ended July 1, 2023 Net revenue $ — $ 3,254 $ 3,254 Net income $ 10,207 $ 1,392 $ (1,074) $ 10,525 Earnings per basic common share $ 2.97 $ 3.07 Earnings per basic diluted share $ 2.97 $ 3.07 (1) Adjustments are related to adjustments made for the following: • Amortization expense of definite-lived intangible assets has been adjusted based on the preliminary fair value at the acquisition date. Soin Pharmaceuticals Effective January 24, 2024, the Company, Amol Soin (“Dr. Soin”), and Soin Therapeutics LLC, a wholly-owned subsidiary of the Company that was had acquired from Dr. Soin entered into an amendment (the “Soin Amendment”) to the parties’ Agreement and Plan of Merger that was dated as of December 28, 2022 (the “Soin Agreement”). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $3.0 million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the “Soin Preferred”) that constituted the consideration under the Soin Agreement. We tendered the first $100,000 amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $100,000, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $2.8 million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation. In connection with the Soin Amendment, the Company reclassified the $3.0 million convertible tranche, originally valued at approximately $2.7 million on our balance sheet, from mezzanine equity to current liabilities, and reclassified the $10.0 million convertible tranche, originally valued at approximately $8.0 million on our balance sheet, to permanent equity. As of June 29, 2024, the outstanding balance in mezzanine equity relates to the $17.0 million convertible tranche originally valued at approximately $3.9 million.

Discontinued Operations

Discontinued Operations	6 Months Ended
Discontinued Operations	Jun. 29, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On March 9, 2023, the Company discontinued operations of its Recycling segment as follows: On March 9, 2023, the Company executed a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which, as of March 1, 2023, the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. As of June 29, 2024 and December 30, 2023, no Recycling assets or liabilities were included in discontinued operations. In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the 26 weeks ended June 29, 2024 and July 1, 2023 have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following: 13 weeks ended 26 Weeks Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Revenues $ — $ — $ — $ 3,795 Cost of revenues — — — 3,992 Gross profit — — — (197) Operating expenses from discontinued operations: Selling, general and administrative expenses $ — $ — — 1,468 Gain on sale of ARCA — — — (15,824) Total operating expenses from discontinued operations — — — (14,356) Operating income from discontinued operations — — — 14,159 Other income (expense) from discontinued operations Interest expense, net — — — (181) Other income expense, net — 1 — (2) Total other income (loss), net — 1 $ — $ (183) Income before provision for income taxes from discontinued operations — 1 — 13,976 Income tax provision (benefit) — (43) — 3,186 Net income from discontinued operations $ — $ 44 $ — $ 10,790 In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 26 weeks ended June 29, 2024 and July 1, 2023 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following: 26 weeks ended June 29, 2024 July 1, 2023 DISCONTINUED OPERATING ACTIVITIES: Net income from discontinued operations — 10,790 Depreciation and amortization — 96 Amortization of debt issuance costs — 11 Amortization of right-of-use assets — 53 Change in deferred taxes — 3,185 Gain on sale of ARCA, net of cash — (15,967) Gain on sale of GeoTraq — — Changes in assets and liabilities: Accounts receivable — 2,932 Inventories — 299 Prepaid expenses and other current assets — 55 Accounts payable and accrued expenses — 866 Net cash provided by operating activities from discontinued operations $ — $ 2,320 DISCONTINUED INVESTING ACTIVITIES: Purchases of property and equipment — (123) Purchase of intangible assets — (33) Net cash used in investing activities from discontinued operations $ — $ (156) DISCONTINUED FINANCING ACTIVITIES: Proceeds from note payable — 5,162 Payment on related party note — (38) Proceeds from issuance of short-term notes payable — (7,291) Payments on notes payable — (45) Net cash used in financing activities from discontinued operations $ — $ (2,212) Effect of changes in exchange rate on cash and cash equivalents — (5) DECREASE IN CASH AND CASH EQUIVALENTS — (53) CASH AND CASH EQUIVALENTS, beginning of period — 53 CASH AND CASH EQUIVALENTS, end of period $ — $ —

Trade and other receivables

Trade and other receivables	6 Months Ended
Trade and other receivables	Jun. 29, 2024
Receivables [Abstract]
Trade and other receivables	Trade and other receivables The Company’s trade and other receivables as of June 29, 2024 and December 30, 2023, respectively, were as follows (in $000’s): June 29, December 30, Trade receivables 865 — Interest receivable - SPYR 69 266 Other receivables 50 — Trade and other receivables, net $ 984 $ 266

Prepaids and other current asse

Prepaids and other current assets	6 Months Ended
Prepaids and other current assets	Jun. 29, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaids and other current assets	Prepaids and other current assets Prepaids and other current assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Prepaid consulting agreements $ 1,145 $ 3 Prepaid insurance 3 72 Prepaid other 512 — Total prepaid expenses and other current assets $ 1,660 $ 75

Property and Equipment

Property and Equipment	6 Months Ended
Property and Equipment	Jun. 29, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment as of June 29, 2024 and December 30, 2023 consist of the following: June 29, 2024 December 30, 2023 Projects under construction $ 1,170 $ — Total property and equipment, net $ 1,170 $ — The Company recorded no depreciation expense from continuing operations for the 26 weeks ended June 29, 2024 and July 1, 2023.

Leases

Leases	6 Months Ended
Leases	Jun. 29, 2024
Leases [Abstract]
Leases	Leases In connection with its acquisition of ALT5 Subsidiary (see Note 3), the Company leases commercial office space. These assets and properties are leased under noncancelable agreements that expire at various future dates. The agreements, which have been classified as operating leases, provide for minimum rent and require the Company to pay all insurance, taxes, and other maintenance costs. As a result, the Company recognizes assets and liabilities for leases with lease terms greater than 12 months. The amounts recognized reflect the present value of remaining lease payments for all leases. The discount rate used is an estimate of the Company’s blended incremental borrowing rate based on information available associated with each subsidiary’s debt outstanding at lease commencement. In considering the lease asset value, the Company considers fixed and variable payment terms, prepayments and options to extend, terminate or purchase. Renewal, termination, or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The following table details the Company's right of use assets and lease liabilities as of June 29, 2024 and December 30, 2023 (in $000's): June 29, 2024 December 30, 2023 Right of use asset - operating leases $ 186 $ — Lease liabilities: Current - operating 59 — Long term - operating 127 — As of June 29, 2024, the weighted average remaining lease term for operating leases is 2.7 years. The Company's weighted average discount rate for operating leases is 11.5%. Total cash payments for operating leases for the 26 weeks ended June 29, 2024 was approximately $39,000. No cash payments for operating leases were made during the 26 weeks ended July 1, 2023. Additionally, the Company recognized approximately $186,000 in right of use assets and liabilities upon commencement of operating leases during the 26 weeks ended June 29, 2024. Total present value of future lease payments of operating leases as of June 29, 2024 (in $000's): Twelve months ended 2025 $ 77 2026 77 2027 65 Total 219 Less implied interest (33) Present value of payments $ 186

Intangible Assets

Intangible Assets	6 Months Ended
Intangible Assets	Jun. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Soin intangibles * $ 19,293 $ 19,293 Customer relationships 13,925 — Trade names 2,675 — Developed technology 1,850 — Patents and domains $ 4 $ 4 Intangible assets 37,747 19,297 Less accumulated amortization (2,751) (1,451) Total intangible assets $ 34,996 $ 17,846 * The Soin intangibles acquired by the Company consist of the following: 1. Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain; 2. Final formula for Naltrexone; and 3. Orphan drug designation as approved by the FDA. Intangible amortization expense was $660,000 and $363,000 for the 13 weeks ended June 29, 2024 and July 1, 2023 and $1.3 million and $726,000 for the 26 weeks ended June 29, 2024 and July 1, 2023.

Marketable Securities

Marketable Securities	6 Months Ended
Marketable Securities	Jun. 29, 2024
Marketable Securities [Abstract]
Marketable Securities	Marketable Securities Marketable securities in connection with SPYR's acquisition of GeoTraq consist of the following (in $000’s, except shares): Series G Convertible Preferred Shares Common Shares Equivalent Amount Beginning Balance, December 30, 2023 9,224 952,442,000 $ 286 Securities received 8,469 846,900,000 84 Mark-to-market — — (190) Ending Balance, March 30, 2024 17,693 1,799,342,000 180 Securities received 25,407 25,407,000,000 434 Mark-to-market — — (180) Ending Balance, June 29, 2024 43,100 27,206,342,000 $ 434

Deposits and Other Assets

Deposits and Other Assets	6 Months Ended
Deposits and Other Assets	Jun. 29, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deposits and Other Assets	Deposits and Other Assets Deposits and other assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Other — 9 Total deposits and other assets $ — $ 9

Accrued Liabilities

Accrued Liabilities	6 Months Ended
Accrued Liabilities	Jun. 29, 2024
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Compensation and benefits 46 37 Accrued guarantees 1,209 3,049 Accrued Legal 397 — Accrued taxes 110 102 Accrued litigation settlement 650 397 Other 26 48 Total accrued expenses $ 2,438 $ 3,633

Debentures

Debentures	6 Months Ended
Debentures	Jun. 29, 2024
Debt Disclosure [Abstract]
Debentures	Debentures Debentures outstanding as of June 29, 2024 and December 30, 2023 consisted for the following (in $000's): June 29, December 30, Interest rate of 12%, maturity date of June 30, 2024 $ 576 $ — Interest rate of 12%, maturity date of June 30, 2025 1,110 — Total debentures $ 1,686 $ — ALT Subsidiary issued 39 debentures over a period from October 2018 through September 2019. The debentures bear interest at 12% per annum and mature as of June 30, 2024 or June 30, 2025, as detailed in the table above. Long-term debt as of June 29, 2024 and December 30, 2023 consisted of the following (in $000's): June 29, December 30, Legacy subsidiary fixed deposits $ 2,134 $ — Legacy subsidiary loan 3,167 — Unaffiliated third-party 1,735 — Other 76 — Total notes payable, related parties 7,112 — Less current portion (3,244) — Total long-term notes payable, related parties $ 3,868 $ — Legacy Subsidiary Fixed Deposits During April 2024, the Company's recently acquired subsidiary, ALT5 Sigma, Inc., entered into several Corporate Fixed Deposit Agreements with otherwise unaffiliated third-parties, pursuant to which the Company became obligated for an aggregate of $2.4 million, as set forth in the respective agreements. Each obligation bears interest at a rate of 12% per annum, and has a maturity date of March 13, 2027. As of June 29, 2024, the outstanding aggregate obligations totaled approximately $2.1 million. Legacy Subsidiary Loan On August 10, 2023, the Company's recently acquired subsidiary, ALT5 Sigma, Inc., entered into an extension agreement for a Bitcoin promissory note with an otherwise unaffiliated third-party. Pursuant to the terms of the extension agreement, the maturity date is August 10, 2024. The promissory note bears interest at 15% per annum. As of June 29, 2024, the outstanding balance of the note was approximately $3.2 million (principal and accrued interest). Unaffiliated Third-Party Loans On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac Capital Group (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. On March 25, 2024, the third party converted $183,000 of the Company's obligation under the ICG Note into 300,000 shares of the Company's common stock, and on April 12, 2024, the third-party converted $60,900 into 100,000 shares of the Company's common stock. As of June 29, 2024, the amount outstanding on the ICG Note was approximately $952,000. On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “Live Note”) in favor of Live Ventures Incorporated (“Live”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its final approvals of the amendments on February 7, 2024. On March 6, 2024, Live entered into a Note Purchase Agreement with with another otherwise unaffiliated third party, under which under which the third party acquired the Live Note. The terms and conditions of the acquired Live Note were not modified in connection with its acquisition by the third party. The principal amount of the Live Note on the date of acquisition was approximately $1.0 million. On March 22, 2024, the third party converted $183,000 of the Company's obligation under the Live Note into 300,000 shares of the Company's common stock, and on April 10, 2024, the third-party converted $60,900 into 100,000 shares of the Company's common stock. As of June 29, 2024, the amount outstanding on the Live Note was approximately $782,000.

Long-Term Debt

Long-Term Debt	6 Months Ended
Long-Term Debt	Jun. 29, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Debentures Debentures outstanding as of June 29, 2024 and December 30, 2023 consisted for the following (in $000's): June 29, December 30, Interest rate of 12%, maturity date of June 30, 2024 $ 576 $ — Interest rate of 12%, maturity date of June 30, 2025 1,110 — Total debentures $ 1,686 $ — ALT Subsidiary issued 39 debentures over a period from October 2018 through September 2019. The debentures bear interest at 12% per annum and mature as of June 30, 2024 or June 30, 2025, as detailed in the table above. Long-term debt as of June 29, 2024 and December 30, 2023 consisted of the following (in $000's): June 29, December 30, Legacy subsidiary fixed deposits $ 2,134 $ — Legacy subsidiary loan 3,167 — Unaffiliated third-party 1,735 — Other 76 — Total notes payable, related parties 7,112 — Less current portion (3,244) — Total long-term notes payable, related parties $ 3,868 $ — Legacy Subsidiary Fixed Deposits During April 2024, the Company's recently acquired subsidiary, ALT5 Sigma, Inc., entered into several Corporate Fixed Deposit Agreements with otherwise unaffiliated third-parties, pursuant to which the Company became obligated for an aggregate of $2.4 million, as set forth in the respective agreements. Each obligation bears interest at a rate of 12% per annum, and has a maturity date of March 13, 2027. As of June 29, 2024, the outstanding aggregate obligations totaled approximately $2.1 million. Legacy Subsidiary Loan On August 10, 2023, the Company's recently acquired subsidiary, ALT5 Sigma, Inc., entered into an extension agreement for a Bitcoin promissory note with an otherwise unaffiliated third-party. Pursuant to the terms of the extension agreement, the maturity date is August 10, 2024. The promissory note bears interest at 15% per annum. As of June 29, 2024, the outstanding balance of the note was approximately $3.2 million (principal and accrued interest). Unaffiliated Third-Party Loans On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac Capital Group (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. On March 25, 2024, the third party converted $183,000 of the Company's obligation under the ICG Note into 300,000 shares of the Company's common stock, and on April 12, 2024, the third-party converted $60,900 into 100,000 shares of the Company's common stock. As of June 29, 2024, the amount outstanding on the ICG Note was approximately $952,000. On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “Live Note”) in favor of Live Ventures Incorporated (“Live”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its final approvals of the amendments on February 7, 2024. On March 6, 2024, Live entered into a Note Purchase Agreement with with another otherwise unaffiliated third party, under which under which the third party acquired the Live Note. The terms and conditions of the acquired Live Note were not modified in connection with its acquisition by the third party. The principal amount of the Live Note on the date of acquisition was approximately $1.0 million. On March 22, 2024, the third party converted $183,000 of the Company's obligation under the Live Note into 300,000 shares of the Company's common stock, and on April 10, 2024, the third-party converted $60,900 into 100,000 shares of the Company's common stock. As of June 29, 2024, the amount outstanding on the Live Note was approximately $782,000.

Related Party Debt

Related Party Debt	6 Months Ended
Related Party Debt	Jun. 29, 2024
Debt Disclosure [Abstract]
Related Party Debt	Related Party Debt Long-term debt payable to related parties (see Note 20) as of June 29, 2024 and December 30, 2023 consisted of the following (in $000's): June 29, December 30, Isaac Capital Group $ — $ 707 Isaac Capital Group, 10% interest rate, matures December 31, 2024 312 — Live Ventures Incorporated, 10% interest rate, matures December 31, 2024 312 — Jon Isaac consulting agreement, 10% interest rate, matures March 4, 2026 516 Isaac Capital Group short-term demand advance, 10% interest rate 100 — Novalk Apps SAA, LLP short-term demand advance, 10% interest rate 220 — Tony Isaac short-term demand advance, 10% interest rate 62 — Total notes payable, related parties 1,522 707 Less current portion (1,006) — Total long-term notes payable, related parties $ 516 $ 707 Twelve months ending June 29, 2025 $ 1,006 2026 516 Total future maturities of long-term debt, related parties $ 1,522 Isaac Capital Group On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac Capital Group (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. On March 25, 2024, the third party converted $183,000 of the Company's obligation under the ICG Note into 300,000 shares of the Company's common stock. As of June 29, 2024, the amount outstanding on the ICG Note was approximately $312,000 (see Note 22). On April 18, 2024, ICG made a short-term demand advance to the Company in the amount of $100,000. The advance bears interest at a rate of 10% per annum until repaid. As of June 29, 2024, the principal amount outstanding was $100,000 (see Note 22). Live Ventures Incorporated On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “Live Note”) in favor of Live Ventures Incorporated (“Live”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its final approvals of the amendments on February 7, 2024. On March 6, 2024, Live entered into a Note Purchase Agreement with another otherwise unaffiliated third party, under which under which the third party acquired the Live Note. The terms and conditions of the acquired Live Note were not modified in connection with its acquisition by the third party. The principal amount of the Live Note on the date of acquisition was approximately $1.0 million. On March 22, 2024, the third party converted $183,000 of the Company's obligation under the Live Note into 300,000 shares of the Company's common stock. As of June 29, 2024, the amount outstanding on the Live Note was approximately $312,000 (see Note 22). Jon Isaac On March 4, 2024, the Company entered into a two-year Consulting Agreement with Jon Isaac, pursuant to which he will provide to the Company (the “Services”): (i) strategic financial advice, including growth strategies, capital allocation, and financial restructuring; (ii) sales and business development advice, including for the acquisition of new clients and new products through networking, referrals, and marketing efforts for our prospective products; (iii) in-depth research and market intelligence on specific industries, sectors, and market trends; (iv) financial models and financial analysis to support strategic decision-making; (v) assistance, through site visits, in the preparation of new client offers and bids for proposed projects; (vi) weekly update calls with management to align on progress of objectives and goals; (vii) enhanced non-confidential materials; (viii) business risk management support; and (ix) other services to which the Company and he may agree that will be memorialized in writing if, when, and as needed during the two-year term. In connection with the Consulting Agreement, the Company entered into a a two-year, straight 10% convertible promissory note in the initial principal amount of $500,000, with an interest rate of 10.0% and a per-share conversion price equivalent to the per-share value of the restricted common stock that he was granted ($1.16). The maturity date of the promissory note is March 4, 2026. As of June 29, 2024, the principal balance outstanding on the promissory note was $516,000 (see Note 22). Novalk Apps SAA, LLP On May 28, 2024 and June 3, 2024, Novalk Apps SAA, LLP (“Novalk”) made short-term demand advances in the amount of $120,000 and $100,000, respectively, to the Company. The advances bears interest at a rate of 10% per annum until repaid. As of June 29, 2024, the principal amount outstanding was $220,000 (see Note 22). Tony Isaac During June 3, 2024, Tony Isaac made a number of short-term demand advances in the aggregate amount of $62,000 to the Company. The advances bears interest at a rate of 10% per annum until repaid. As of June 29, 2024, the principal amount outstanding was $62,000 (see Note 22).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 29, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation SEC Complaint On August 2, 2021, the U.S. Securities and Exchange Commission (“SEC”) filed a civil complaint (the “SEC Complaint”) in the United States District Court for the District of Nevada naming the Company and one of its executive officers, Virland Johnson, the Company's Chief Financial Officer, as defendants (collectively, the “Defendants”). Pursuant to an agreed-upon Order of the Court, on May 28, 2024, the Company settled its litigation with the SEC. The Settlement Agreement provided, in pertinent part: “Without admitting or denying the allegations of the complaint (except as provided herein in paragraph 12 and except as to personal and subject matter jurisdiction, which [the Company] admits), [the Company] hereby consents to the entry of the final Judgment in the form attached hereto (the “Final Judgment”) and incorporated by reference herein, which, among other things: “(a) permanently restrains and enjoins [the Company] from violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder [15 U.S.C. § 78j(b) and 17 C.F.R. §§ 240.10b-5]; and (c)[sic] orders [the Company] to pay a civil penalty in the amount of $250,000 under Section 21(d)(3) of the Exchange Act [15 U.S.C. § 78u(d)(3)).” The SEC has agreed to accept four quarterly payments from the Company, each in the amount of $62,500. The Settlement Agreement is attached to the Order as Exhibit 1, both of which documents may be viewed at https://ecf.nvd.uscourts.gov/doc1/115110470966. The SEC Complaint's remaining allegations relate to financial, disclosure and reporting violations against the executive officer under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5. The SEC Complaint also alleges various claims against the executive officer under Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) and 13(b)(5) of the Exchange Act and Rules 12b-20, 13a-1, 13a-13, 13a-14, 13b2-1, and 13b2-2. The SEC continues to seek a permanent injunction, civil penalties, and an officer-and-director bar against the executive officer. The foregoing is only a general summary of the SEC Complaint, which may be accessed on the SEC’s website at https://www.sec.gov/litigation/litreleases/2021/lr25155.htm. Skybridge On December 29, 2016, the Company served a Minnesota state court complaint for breach of contract on Skybridge Americas, Inc. (“SA”), the Company’s primary call center vendor throughout 2015 and most of 2016. The Company and SA held a mediation session in July 2020. Trial was held in August 2020 and on February 1, 2021, the District Court assessed damages against the Company in the amount of approximately $715,000 plus interest, fees, and costs and attorneys’ fees of $475,000. In subsequent proceedings, the Appeals Court affirmed the District Court judgment. Of the total amount awarded to SA, less the funds that the Company had previously deposited with the District Court, SA remained entitled to approximately $422,000 of statutory interest, which obligation was assumed by the buyer in connection with the Company's disposition of ARCA and its subsidiaries. On April 10, 2024, SA sold its judgment to an otherwise unaffiliated third party for the face value of the judgment and the interest accrued thereon through that date (an aggregate of $433,920.03), plus accrued legal fees (in the amount of $18,123.50) to which SA was entitled in accordance with the terms of the underlying agreement with the Company and with the judgment. The purchaser agreed to forbear from enforcing the judgment, subject to the Company’s repayment or his conversion thereof. In connection with the third-party’s forbearance, the Company issued its promissory note to such person in the initial principal amount of 147,956.47, which bears interest at the rate of 10% per annum, and, as with the underlying judgment, is convertible into shares of the Company’s common stock at a fixed per-share conversion price of $2.60. GeoTraq On or about April 9, 2021, GeoTraq, Gregg Sullivan, Tony Isaac, and we, among others, resolved all of their claims that related to, among other items, the Company's acquisition of GeoTraq in August 2017, all post-acquisition activities, and Mr. Sullivan’s post-acquisition employment relationship with GeoTraq (all of such claims, the “GeoTraq Matters”). The resolution was effectuated through the parties’ execution and delivery of a Settlement Agreement and Mutual Agreement of Claims (the “GeoTraq Settlement Agreement”). Under the terms of the Settlement Agreement, the Company, on its own behalf and on behalf of GeoTraq and Mr. Isaac, agreed to tender to Mr. Sullivan an aggregate of $1.95 million (the “GeoTraq Settlement Consideration”) in the following manner: (i) $250,000, which was tendered in cash on or about the date of the Settlement Agreement and (ii) up to 10 quarterly installments of not less than $170,000 that commenced on June 1, 2021, and continued not less frequently than every three months thereafter (the “GeoTraq Installments”). The Company may tender the GeoTraq Installments in cash or in the equivalent value of shares of its common stock (the value of the shares to be determined by a formula set forth in the Settlement Agreement), in either case at the Company's discretion. The Company may also prepay one or more GeoTraq Installments in full or in part at any time or from time to time either in cash or in shares of its common stock (a “GeoTraq Prepayment”). If the Company elected to prepay one or more GeoTraq Installments with shares of its common stock, Mr. Sullivan reserved the right not to consent to a tender thereof in excess of 50% of the value of that specific GeoTraq Prepayment; however, Mr. Sullivan was restricted in the reasons for which he can refuse to provide his written consent. The number of shares of the Company's common stock to be issued upon any GeoTraq Prepayment is determined by a different formula than the one to be utilized for a GeoTraq Installment. On March 17, 2023, the Company converted 5,185 of Mr. Sullivan’s Series A-1 Preferred shares and issued 103,707 shares of the Company's common stock as payment for its quarterly installment. On June 1, 2023, the Company converted 7,697 of Mr. Sullivan’s Series A-1 Preferred shares into 153,941 shares of the Company’s common stock in payment of its June 30, 2023 quarterly installment. On September 1, 2023, the Company converted 14,471 of Mr. Sullivan’s Series A-1 Preferred shares into 289,421 shares of the Company’s common stock in payment of its September 30, 2023 quarterly installment. As of September 30, 2023, the full balance due under the Settlement Agreement had been repaid and the remaining 1,505 shares of Mr. Sullivan’s Series A-1 Preferred shares were returned to the Company for cancellation without any further consideration. The parties to the Settlement Agreement released and forever discharged one another from any and all known and unknown claims that were asserted or could have been asserted arising out of the GeoTraq Litigation Matters. Alixpartners, LLC On October 19, 2022, Alixpartners, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, styled Alixpartners, LLC, plaintiff/petitioner, against JanOne Inc., Index No. 653877/2022. Plaintiff alleged the breach of an agreement and sought damages in the amount of approximately $345,000. The Company denied that obligation. After extensive negotiations, the parties reached a settlement, pursuant to which the Company agreed to pay to Alixpartners the sum of $125,000 in two tranches and to provide a confession of judgment in its favor in the amount of approximately $450,000, which represented the amount sought in the complaint plus interest thereon. The confession of judgment will be null and void and the complaint will be dismissed with prejudice upon the Company tendering both tranches timely. The Company tendered both settlement payments in May 2023, and the complaint was subsequently dismissed. Sieggreen In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, regarding which, as of the date of these financial statements, the Court has not ruled. The Court has set a hearing on the Motion to Dismiss for August 28, 2024. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims. Main/270 The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant, Case no.: 2:22-cv-01938-ALM-EPD. The Company was a guarantor of the lease between the Plaintiff and ApplianceSmart, Inc. Plaintiff alleged a cause of action against the Company in respect of the guaranty and seeks approximately $90,000 therefor. Plaintiff also seeks approximately $1,420,000 against ApplianceSmart and the Company on a joint and several basis. The Company and Live Ventures Incorporated (“Live Ventures”), the parent company of ApplianceSmart, have an agreement, pursuant to which all attorney's fees and any judgment will be divided equally between the parties. Nevertheless, the Company does not believe that it is obligated to Plaintiff in that amount and the parties continue to negotiate a potential settlement. Westerville Square In an attempt to recover payments due under a lease, in 2021, Westerville Square, Inc., as the landlord, initiated a civil action against the Company, styled Westerville Square, Inc. v. Appliance Recycling Centers Of America, Inc., et al., in the Court of Common Pleas of Franklin County, Ohio, Case No. 19 CV 8627. The case was stayed during the bankruptcy proceedings of ApplianceSmart, Inc., and was reinstated on June 7, 2021. The landlord is currently seeking $120,000, which amount is disputed by the Company. Effective June 4, 2023, the parties settled the matter, pursuant to which settlement the Company tendered the sum of $110,000 to the landlord, the parties entered into a Settlement Agreement and Release, and the case was dismissed with prejudice. Other Commitments On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures, a related party. In connection with that sale, as of January 2, 2021, the Company accrued an aggregate amount of future real property lease payments of approximately $767,000 which represented amounts guaranteed or which may have been owed under certain lease agreements to three third party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (“ApplianceSmart Leases”). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December 30, 2023, the Company reversed approximately $637,000 of the accrual, as the Company is no longer liable for two of these guarantees upon ApplianceSmart's emergence from bankruptcy. As of December 30, 2023, a balance of approximately $130,000 remains as an accrued liability due to an ongoing dispute concerning one of the leases. The Company and Live Ventures have agreed to divide in half between them any ultimate balance owing thereunder and any attorneys’ fees expended in relation thereto.. The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of June 29, 2024.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 29, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock : Our Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences, and designations as the Board of Directors may determine. During the 13 weeks ended June 29, 2024 and July 1, 2023, no shares of common stock were issued in lieu of professional services. On August 18, 2023, the Company entered into a Securities Purchase Agreement with a certain institutional investor for the sale by the Company in a registered direct offering of: (i) 418,000 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $0.8811 per share and (ii) pre-funded warrants exercisable for up to 481,348 shares of Common Stock to the Investor at an offering price equal to $0.8801 per pre-funded Warrant. In connection with the Securities Purchase Agreement, during the 13 weeks ended March 30, 2024, the Company issued 27,738 shares of its common stock to three third-parties in exchange for brokerage services. On October 9, 2023, the stockholders approved the Company's 2023 Equity Incentive Plan (the “2023 Plan”) at its Annual Meeting of Stockholders held in October 2023, the Company's Compensation Committee awarded 908,852 Restricted Stock Units (“RSU's”) to various employees of the Company. The RSU's were immediately vested, and the total value of the award was $345,000 based upon the closing price of $0.3796 of the Company's stock on October 9, 2023. The 2023 Plan having been approved by stockholders, 908,852 shares of the Company's common stock were issued during the 13 weeks ended March 30, 2024. On February 23, 2024, the Company entered into Unit Purchase Agreements with two otherwise unaffiliated third-party investors, pursuant to which each Investor agreed to purchase 408,163 units of securities from the Company, at a price per Unit of $0.7350, for an aggregate purchase price of $300,000 per investor for an aggregate price of $600,000. Each Unit consists of one share of the Company’s common stock and one warrant to purchase an additional share of common stock. The per-Unit price is allocated as follows: $0.61 per share of common stock and $0.125 per Warrant. The Warrant has a three-year term and will be immediately exercisable. Each Warrant is exercisable at $0.61 per share. The Company intends to use the proceeds from the Unit Purchases for its working capital needs. Further, the Company issued an additional 81,632 shares of its common stock to another party in exchange for brokerage services rendered. On March 4, 2024, the Company entered into a two-year Consulting Agreement (the “Consulting Agreement”) with Jon Isaac, pursuant to which he will provide a variety of services to the Company. In connection with the Consulting Agreement, the Company issued to Mr. Isaac 200,000 restricted shares of its common stock (see Note 22). On March 22, 2024, pursuant to the terms and conditions of a promissory note, the Company converted $183,000 of obligations into 300,000 shares of the Company's common stock (see Note 22). On March 25, 2024, pursuant to the terms and conditions of a promissory note, the Company converted $183,000 of obligations into 300,000 shares of the Company's common stock (see Note 22). On April 10, 2024, pursuant to the terms and conditions of a promissory note, the Company converted $60,900 of obligations into 100,000 shares of the Company's common stock (see Note 22). On April 12, 2024, pursuant to the terms and conditions of a promissory note, the Company converted $60,900 of obligations into 100,000 shares of the Company's common stock (see Note 22). On Mar 4, 2024, the Company entered into an Asset Purchase Agreement for the purchase of specified assets of North York LTD. For the purchase of the assets, the Company (i) issued 300,000 restricted shares of its common stock, (ii) issued 5,000 shares of its Series V Convertible Preferred Stock, and (iii) granted a three-year warrant for the purchase of up to 125,000 shares of its common stock at an exercise price of $1.25 per share. On May 1, 2024, the Company entered into a Securities Purchase Agreement with two institutional investors for the sale by the Company of 79,782 units of the Company's securities at a purchase price of $3.775 per unit, each unit consisting of one share of the Company's common stock and one common stock purchase warrant for the purchase of an additional share of Common Stock. Each three-year warrant is exercisable immediately at an exercise price of $3.63 per share. The gross proceeds were approximately $300,000, before deducting related expenses. On May 15, 2024, the Company acquired ALT5 Subsidiary. As consideration under the acquisition, the Company issued 1,799,100 shares of its common stock to the legacy equity holders of the capital stock of ALT5 (see Note 3). On June 3, 2024, the Company entered into a six-month marketing agreement with a non-affiliated third-party, pursuant to which the third-party will provide a variety of marketing-related services to the Company. In connection with the marketing agreement, the Company issued to the third-party 47,923 shares of its common stock. On June 6, 2024, the Company entered into a one-year consulting agreement with a non-affiliated third-party, pursuant to which the third-party will provide a variety of finance and investor-related services to the Company. In connection with the marketing agreement, the Company issued to the third-party 150,000 shares of its common stock. During the three months ended June 29, 2024, the Company issued an aggregate of 295,000 shares of its common stock to four individuals under the Company's 2023 Equity Incentive Plan. The aggregate value of the shares at issuance was approximately $1.2 million. As of June 29, 2024, and December 30, 2023, there were 12,589,015 and 4,957,647 shares, respectively, of common stock issued and outstanding. Stock Options : The Company's 2023 Plan, which was adopted by the Board in August 2023 and approved by the stockholders at the 2023 Annual Meeting of Stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 13 and 26 weeks ended June 29, 2024, the Company recognized $1.2 million and $1.5 million, respectively, in share-based compensation expense related to the 908,852 RSU's that were awarded and immediately vested, as well as 295,000 shares of the Company's common stock issued (see above). The Company's 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of June 29, 2024 and December 30, 2023, 100,000 options were outstanding under the 2016 Plan. The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of June 29, 2024 and December 30, 2023, 14,000 were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. There were no stock options granted during the 13 and 26 weeks ended June 29, 2024. Additional information relating to all outstanding options is as follows: Options Weighted Aggregate Weighted Outstanding at December 30, 2023 114,000 $ 5.68 $ — 6.1 Outstanding at March 30, 2024 114,000 $ 5.68 $ 11 5.9 Cancelled/expired (6,000) $ 17.35 Balance at June 29, 2024 108,000 $ 5.03 $ 7 6.0 Exercisable at June 29, 2024 108,000 $ 5.03 $ 7 6.0 The Company recognized approximately $1.2 million and $4,000 of share-based compensation expense for the 13 weeks ended June 29, 2024 and July 1, 2023, respectively, and approximately $1.5 million and $12,000 of share-based compensation expense for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively. As of June 29, 2024, the Company had no unrecognized share-based compensation expense associated with equity awards. Series A-1 Preferred Stock 123,750 shares were converted during the 26 weeks ended June 29, 2024. As of June 29, 2024 and December 30, 2023, respectively, there were 69,980 and 193,730 shares of Series A-1 Preferred Stock outstanding. Series S Preferred Stock On December 28, 2022 the Company acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30.0 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. Shares of Series S Convertible Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. As of June 29, 2024 and December 30, 2023, there were 100,000 shares of Series S Convertible Preferred Stock outstanding.

Mezzanine Equity

Mezzanine Equity	6 Months Ended
Mezzanine Equity	Jun. 29, 2024
Mezzanine equity [Abstract]
Mezzanine Equity	Mezzanine Equity Series S Preferred Stock During the 26 weeks ended June 29, 2024, the Company reclassified approximately $2.7 million from mezzanine equity to current liabilities, and approximately $8.0 million from mezzanine equity to permanent equity (see Note 3). Consequently, as of June 29, 2024, the outstanding balance in mezzanine equity was approximately $3.9 million.

Earnings Per Share

Earnings Per Share	6 Months Ended
Earnings Per Share	Jun. 29, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Net income (loss) per share is calculated using the weighted average number of shares of common stock outstanding during the applicable period. Basic weighted average common shares outstanding do not include shares of restricted stock that have not yet vested, although such shares are included as outstanding shares in the Company’s Consolidated Balance Sheet. Diluted net income (loss) per share is computed using the weighted average number of common shares outstanding and if dilutive, potential common shares outstanding during the period. Potential common shares consist of the additional common shares issuable in respect of restricted share awards, stock options and convertible preferred stock. The following table presents the computation of basic and diluted net income (loss) per share (in $000’s, except share and per–share data): For the Thirteen Weeks Ended For the Twenty-Six Weeks Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Continuing Operations Basic Net income (loss) from continuing operations $ 589 $ 79 $ (1,555) $ (583) Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Basic income (loss) per share from continuing operations $ 0.07 $ 0.02 $ (0.18) $ (0.17) Diluted Net income (loss) from continuing operations $ 589 $ 79 $ (1,555) $ (583) Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Diluted income (loss) per share from continuing operations $ 0.07 $ 0.02 $ (0.18) $ (0.17) Discontinued Operations Basic Net income from discontinued operations $ — $ 44 $ — $ 10,790 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Basic income per share from discontinued operations $ — $ 0.01 $ — $ 3.14 Diluted Net income from discontinued operations $ — $ 44 $ — $ 10,790 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Diluted income per share from discontinued operations $ — $ 0.01 $ — $ 3.14 Total Basic Net income $ 589 $ 123 $ (1,555) $ 10,207 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Basic income per share $ 0.07 $ 0.03 $ (0.18) $ 2.97 Diluted Net income $ 589 $ 123 $ (1,555) $ 10,207 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Diluted income per share $ 0.07 $ 0.03 $ (0.18) $ 2.97 Potentially dilutive securities totaling 108,000 and 114,000 were excluded from the calculation of diluted earnings per share for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively, because the effects were anti-dilutive based on the application of the treasury stock method. Additionally, 69,980 shares of Series A-1 Preferred Stock, convertible into 1.4 million of the Company's common stock, and 100,000 shares of Series S Preferred Stock, convertible into 3.0 million shares of the Company's common stock (subject to certain contractual, event-based, and temporal limitations), were excluded from the calculation of diluted earnings per share as, by agreement, these shares could not be converted as of June 29, 2024.

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 29, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company recorded an income tax benefit from continuing operations of approximately $2.9 million and $17,000 for the 13 weeks ended June 29, 2024 and July 1, 2023, respectively, and an income tax benefit from discontinued operations of $0 and an income tax expense of $43,000 for the 13 weeks ended June 29, 2024 and July 1, 2023, respectively. The Company recorded an income tax benefit from continuing operations of approximately $2.9 million and $244,000 for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively, and an income tax expense from discontinued operations of $0 and $3.2 million for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively. The Company’s overall effective tax rate was 65.3% and 29.5% for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively. The effective tax rates and related provisional tax amounts vary from the U.S. federal statutory rate primarily due to state taxes and the release of a valuation allowance in the United States.

Segment Information

Segment Information	6 Months Ended
Segment Information	Jun. 29, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information The Company operates within targeted markets through three reportable segments for continuing operations: Biotechnology, Fintech, and Recycling. The Biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The Fintech segment commenced operations during May 2024 with the acquisition of ALT5 Subsidiary (see Note 3), which provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. The Recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The Recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (“CODM”). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers. Due the sale of Company's Recycling segment during March 2023, it is being presented as discontinued operations for the 13 and 26 weeks ended July 1, 2023. The following tables present our segment information for the 13 and 26 weeks ended June 29, 2024 and July 1, 2023 (in $000’s): Thirteen Weeks Ended Twenty-Six Weeks Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Revenues Biotechnology $ — $ — $ — $ — Fintech 2,169 — 2,169 — Discontinued operations — — — 3,795 Total Revenues $ 2,169 $ — $ 2,169 $ 3,795 Gross profit Biotechnology $ — $ — $ — $ — Fintech 1,098 — 1,098 — Discontinued operations — — — (197) Total Gross profit $ 1,098 $ — $ 1,098 $ (197) Operating income (loss) Biotechnology $ (3,177) $ (1,060) $ (4,983) $ (2,159) Fintech 261 — 261 — Discontinued operations — — — 14,159 Total Operating income (loss) $ (2,916) $ (1,060) $ (4,722) $ 12,000 Depreciation and amortization Biotechnology $ — $ 362 $ — $ 726 Fintech 179 — 179 — Discontinued operations — — — 96 Total Depreciation and amortization $ 179 $ 362 $ 179 $ 822 Interest (income) expense, net Biotechnology $ (161) $ (365) $ 91 $ (840) Fintech 157 — 157 — Discontinued operations — — — 181 Total Interest expense, net $ (4) $ (365) $ 248 $ (659) Net income (loss) before income taxes Biotechnology $ (3,112) $ 62 $ (5,331) $ (827) Fintech 850 — 850 — Discontinued operations — 1 — 13,976 Total Net income before income taxes $ (2,262) $ 63 $ (4,481) $ 13,149

Related Parties

Related Parties	6 Months Ended
Related Parties	Jun. 29, 2024
Related Party Transactions [Abstract]
Related Parties	Related Parties Shared Services Tony Isaac, the Company’s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures and managing member of Isaac Capital Group LLC (“ICG”). Tony Isaac, Chief Executive Officer, and Richard Butler, Board of Directors member of the Company, are members of the Board of Directors of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $0 and $55,000 for the 13 weeks ended June 29, 2024 and July 1, 2023, respectively, and $0 and $87,000 for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively. Customer Connexx rented approximately 9,900 square feet of office space from Live Ventures in Las Vegas, Nevada. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, the Company ceased leasing office space in the Las Vegas, Nevada facility. The total rent and common area expense was approximately $34,000 and $67,000 for the 13 weeks ended June 29, 2024 and July 1, 2023, respectively, and approximately $109,000 and $103,000 for the 26 weeks ended June 29, 2024 and July 1, 2023, respectively. Notes with Live Ventures and ICG On February 7, 2024, the Company entered into a promissory notes with each of Live Ventures and ICG. The initial principal amount of each note is $300,000, with an interest rate of 10% per annum. Pursuant to an amendment to each note, $100,000 of principal, and accrued interest thereon, is due on September 7, 2024 for each note, and the balance of each note is due on December 31, 2024. At the Company’s option, the obligation under each note is convertible after the six-month anniversary thereof at a per-share conversion price of $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors approved the issuance of the two notes on February 7, 2024. As of June 29, 2024, the principal balances outstanding on each of the promissory notes was $312,000. Isaac Consulting Agreement On March 4, 2024, the Company entered into a two-year Consulting Agreement with Jon Isaac, pursuant to which he will provide to the Company (the “Services”): (i) strategic financial advice, including growth strategies, capital allocation, and financial restructuring; (ii) sales and business development advice, including for the acquisition of new clients and new products through networking, referrals, and marketing efforts for our prospective products; (iii) in-depth research and market intelligence on specific industries, sectors, and market trends; (iv) financial models and financial analysis to support strategic decision-making; (v) assistance, through site visits, in the preparation of new client offers and bids for proposed projects; (vi) weekly update calls with management to align on progress of objectives and goals; (vii) enhanced non-confidential materials; (viii) business risk management support; and (ix) other services to which the Company and he may agree that will be memorialized in writing if, when, and as needed during the two-year term. As compensation for the Services, the Company agreed to (i) assign to him two universal life insurance policies that relate to the life of one of the founders of our now-disposed legacy recycling business (the first policy has an accumulated value/surrender value of approximately $3,854 and the second has an accumulated value/surrender value of approximately $468); (ii) contingently tender to him funds in our Canadian counsel’s trust account in the event that the prospective Order of the Court of Appeal for Ontario Canada in the matter styled, Amtim Capital Inc. and Appliance Recycling Centers of America, Case No. COA-23-CV-0156, becomes the final Order of the Court, which amount we estimated not to exceed approximately US$220,000; (iii) issue to him 200,000 restricted shares of our common stock with the per-share value being the average of the Nasdaq historical NOCP closing price during the five trading days prior to our board approving the Consulting Agreement, which shares were awarded from our 2023 Equity Incentive Plan; and (iv) a two-year, straight 10% convertible promissory note in the initial principal amount of $500,000, with an interest rate of 10.0% and a per-share conversion price equivalent to the per-share value of the restricted common stock that he was granted ($1.16). The maturity date of the promissory note is March 4, 2026. The value of the restricted shares was $232,000 on the date issued. As of June 29, 2024, the principal balance outstanding on the promissory note was $516,000. Short-Term Advances On April 18, 2024, ICG made a short-term demand advance to the Company in the amount of $100,000. The advance bears interest at a rate of 10% per annum until repaid. As of June 29, 2024, the principal amount outstanding was $100,000. On May 28, 2024 and June 3, 2024, Novalk made short-term demand advances in the amount of $120,000 and $100,000, respectively, to the Company. Juan Yunis, an employee of Live Ventures, is the managing member of Novalk. The advances bears interest at a rate of 10% per annum until repaid. As of June 29, 2024, the principal amount outstanding was $220,000. During June 3, 2024, Tony Isaac made a number of short-term demand advances in the aggregate amount of $62,000 to the Company. The advances bears interest at a rate of 10% per annum until repaid. As of June 29, 2024, the principal amount outstanding was $62,000 (see Note 22).

Subsequent event

Subsequent event	6 Months Ended
Subsequent event	Jun. 29, 2024
Subsequent Events [Abstract]
Subsequent event	Subsequent event The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no events that have occurred that would require adjustments to disclosures in its condensed consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 29, 2024
Accounting Policies [Abstract]
Basis of Presentation	B asis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 30, 2023.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications	Reclassifications Certain amounts in the prior period have been reclassified to conform to the current period presentation. These reclassifications have no material effect on the reported financial results.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, the Series B and Series M preferred stock issued in the transaction, pursuant to which the Company acquired the ALT5 Subsidiary, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.
Financial Instruments	Financial Instruments Financial instruments consist primarily of cash equivalents, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments.
Digital Assets and other Receivables	Digital Assets and other Receivables
Digital Assets and other Payables	Digital Assets and other Payables
Revenue Recognition	Revenue Recognition Revenue recognition applies to the Company's Fintech segment only, as the Company's Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements: 1. Executed contracts with the Company’s customers that it believes are legally enforceable; 2. Identification of performance obligations in the respective contract; 3. Determination of the transaction price for each performance obligation in the respective contract; 4. Allocation of the transaction price to each performance obligation; and 5. Recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to each of the Company’s revenue category, is summarized below: 1. Product sales – revenue is recognized at the time of sale of equipment to the customer. 2. Service sales – revenue is recognized based on when the service has been provided to the customer. The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis. The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets. The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided.
Stock-Based Compensation	Stock-Based Compensation The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Mergers and Acquisitions (Table

Mergers and Acquisitions (Tables)	6 Months Ended
Mergers and Acquisitions (Tables)	Jun. 29, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Fair Value Adjustments for Shares of Series B and Series M Preferred Stock	The fair value of the purchase price components outlined above was $16.0 million due to fair value adjustments for the shares of Series B and Series M Preferred Stock, as detailed below (in $000’s): Common stock $ 7,448 Series B preferred stock 8,552 Total purchase price $ 16,000
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The table below outlines the purchase price allocation of the purchase for ALT5 Subsidiary to the acquired identifiable assets, liabilities assumed and goodwill (in $000’s): Total purchase price $ 16,000 Accounts payable 267 Digital assets payable 16,763 Debt 7,613 Total liabilities assumed 24,643 Total consideration 40,643 Cash 5,853 Accounts receivable 2,917 Digital assets receivable 9,082 Intangible assets Customer relationships $ 13,925 Trade names 2,675 Developed technology 1,850 Subtotal intangible assets 18,450 Other 492 Total assets acquired 36,794 Total goodwill $ 3,849
Schedule of Proforma Information	The table below presents selected proforma information for the Company for the thirteen and twenty-six week periods ended June 29, 2024, assuming that the acquisition had occurred on January 1, 2023 (the beginning of the Company’s 2023 fiscal year), pursuant to ASC 805-10-50 (in $000's). This proforma information does not purport to represent what the actual results of operations of the Company would have been had the acquisition occurred on that date, nor does it purport to predict the results of operations for future periods. As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 13 weeks ended June 29, 2024 ALT5 Subsidiary Unaudited 13 weeks ended June 29, 2024 Adjustments(1) ALT5 Sigma Corporation for the 13 weeks ended June 29, 2024 Net revenue $ 2,169 $ 693 $ 2,862 Net income $ 589 $ 206 $ (269) $ 526 Earnings per basic common share $ 0.07 $ 0.06 Earnings per basic diluted share $ 0.07 $ 0.06 As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 13 weeks ended July 1, 2023 ALT5 Subsidiary Unaudited 13 weeks ended July 1, 2023 Adjustments(1) ALT5 Sigma Corporation for the 13 weeks ended July 1, 2023 Net revenue $ — $ 2,021 $ 2,021 Net income $ 123 $ 1,157 $ (537) $ 743 Earnings per basic common share $ 0.03 $ 0.20 Earnings per basic diluted share $ 0.03 $ 0.20 As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 26 weeks ended June 29, 2024 ALT5 Subsidiary Unaudited 26 weeks ended June 29, 2024 Adjustments(1) ALT5 Sigma Corporation for the 26 weeks ended June 29, 2024 Net revenue $ 2,169 $ 2,918 $ 5,087 Net income $ (1,555) $ 71 $ (806) $ (2,290) Earnings per basic common share $ (0.18) $ (0.27) Earnings per basic diluted share $ (0.18) $ (0.27) As Reported Adjustments Proforma ALT5 Sigma Corporation Unaudited 26 weeks ended July 1, 2023 ALT5 Subsidiary Unaudited 26 weeks ended July 1, 2023 Adjustments(1) ALT5 Sigma Corporation for the 26 weeks ended July 1, 2023 Net revenue $ — $ 3,254 $ 3,254 Net income $ 10,207 $ 1,392 $ (1,074) $ 10,525 Earnings per basic common share $ 2.97 $ 3.07 Earnings per basic diluted share $ 2.97 $ 3.07 (1) Adjustments are related to adjustments made for the following: • Amortization expense of definite-lived intangible assets has been adjusted based on the preliminary fair value at the acquisition date.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
Discontinued Operations (Tables)	Jun. 29, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations in Consolidated Statements of Operations and Cash Flows	The results of operations for these entities for the 26 weeks ended June 29, 2024 and July 1, 2023 have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following: 13 weeks ended 26 Weeks Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Revenues $ — $ — $ — $ 3,795 Cost of revenues — — — 3,992 Gross profit — — — (197) Operating expenses from discontinued operations: Selling, general and administrative expenses $ — $ — — 1,468 Gain on sale of ARCA — — — (15,824) Total operating expenses from discontinued operations — — — (14,356) Operating income from discontinued operations — — — 14,159 Other income (expense) from discontinued operations Interest expense, net — — — (181) Other income expense, net — 1 — (2) Total other income (loss), net — 1 $ — $ (183) Income before provision for income taxes from discontinued operations — 1 — 13,976 Income tax provision (benefit) — (43) — 3,186 Net income from discontinued operations $ — $ 44 $ — $ 10,790 26 weeks ended June 29, 2024 July 1, 2023 DISCONTINUED OPERATING ACTIVITIES: Net income from discontinued operations — 10,790 Depreciation and amortization — 96 Amortization of debt issuance costs — 11 Amortization of right-of-use assets — 53 Change in deferred taxes — 3,185 Gain on sale of ARCA, net of cash — (15,967) Gain on sale of GeoTraq — — Changes in assets and liabilities: Accounts receivable — 2,932 Inventories — 299 Prepaid expenses and other current assets — 55 Accounts payable and accrued expenses — 866 Net cash provided by operating activities from discontinued operations $ — $ 2,320 DISCONTINUED INVESTING ACTIVITIES: Purchases of property and equipment — (123) Purchase of intangible assets — (33) Net cash used in investing activities from discontinued operations $ — $ (156) DISCONTINUED FINANCING ACTIVITIES: Proceeds from note payable — 5,162 Payment on related party note — (38) Proceeds from issuance of short-term notes payable — (7,291) Payments on notes payable — (45) Net cash used in financing activities from discontinued operations $ — $ (2,212) Effect of changes in exchange rate on cash and cash equivalents — (5) DECREASE IN CASH AND CASH EQUIVALENTS — (53) CASH AND CASH EQUIVALENTS, beginning of period — 53 CASH AND CASH EQUIVALENTS, end of period $ — $ —

Trade and other receivables (Ta

Trade and other receivables (Tables)	6 Months Ended
Trade and other receivables (Tables)	Jun. 29, 2024
Receivables [Abstract]
Schedule of Trade and Other Receivables	The Company’s trade and other receivables as of June 29, 2024 and December 30, 2023, respectively, were as follows (in $000’s): June 29, December 30, Trade receivables 865 — Interest receivable - SPYR 69 266 Other receivables 50 — Trade and other receivables, net $ 984 $ 266

Prepaids and other current as_2

Prepaids and other current assets (Tables)	6 Months Ended
Prepaids and other current assets (Tables)	Jun. 29, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaids and Other Current Assets	Prepaids and other current assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Prepaid consulting agreements $ 1,145 $ 3 Prepaid insurance 3 72 Prepaid other 512 — Total prepaid expenses and other current assets $ 1,660 $ 75

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
Property and Equipment (Tables)	Jun. 29, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of June 29, 2024 and December 30, 2023 consist of the following: June 29, 2024 December 30, 2023 Projects under construction $ 1,170 $ — Total property and equipment, net $ 1,170 $ —

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Jun. 29, 2024
Leases [Abstract]
Schedule of Company's Right of Use Assets and Lease Liabilities	The following table details the Company's right of use assets and lease liabilities as of June 29, 2024 and December 30, 2023 (in $000's): June 29, 2024 December 30, 2023 Right of use asset - operating leases $ 186 $ — Lease liabilities: Current - operating 59 — Long term - operating 127 —
Schedule of Present Value of Future Lease Payments of Operating Leases	Total present value of future lease payments of operating leases as of June 29, 2024 (in $000's): Twelve months ended 2025 $ 77 2026 77 2027 65 Total 219 Less implied interest (33) Present value of payments $ 186

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
Intangible Assets (Tables)	Jun. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Soin intangibles * $ 19,293 $ 19,293 Customer relationships 13,925 — Trade names 2,675 — Developed technology 1,850 — Patents and domains $ 4 $ 4 Intangible assets 37,747 19,297 Less accumulated amortization (2,751) (1,451) Total intangible assets $ 34,996 $ 17,846 * The Soin intangibles acquired by the Company consist of the following: 1. Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain; 2. Final formula for Naltrexone; and 3. Orphan drug designation as approved by the FDA.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
Marketable Securities (Tables)	Jun. 29, 2024
Marketable Securities [Abstract]
Schedule of Marketable Securities	Marketable securities in connection with SPYR's acquisition of GeoTraq consist of the following (in $000’s, except shares): Series G Convertible Preferred Shares Common Shares Equivalent Amount Beginning Balance, December 30, 2023 9,224 952,442,000 $ 286 Securities received 8,469 846,900,000 84 Mark-to-market — — (190) Ending Balance, March 30, 2024 17,693 1,799,342,000 180 Securities received 25,407 25,407,000,000 434 Mark-to-market — — (180) Ending Balance, June 29, 2024 43,100 27,206,342,000 $ 434

Deposits and Other Assets (Tabl

Deposits and Other Assets (Tables)	6 Months Ended
Deposits and Other Assets (Tables)	Jun. 29, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Deposits and Other Assets	Deposits and other assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Other — 9 Total deposits and other assets $ — $ 9

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
Accrued Liabilities (Tables)	Jun. 29, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s): June 29, December 30, Compensation and benefits 46 37 Accrued guarantees 1,209 3,049 Accrued Legal 397 — Accrued taxes 110 102 Accrued litigation settlement 650 397 Other 26 48 Total accrued expenses $ 2,438 $ 3,633

Debentures (Tables)

Debentures (Tables)	6 Months Ended
Debentures (Tables)	Jun. 29, 2024
Debt Disclosure [Abstract]
Schedule of Debentures Outstanding	Debentures outstanding as of June 29, 2024 and December 30, 2023 consisted for the following (in $000's): June 29, December 30, Interest rate of 12%, maturity date of June 30, 2024 $ 576 $ — Interest rate of 12%, maturity date of June 30, 2025 1,110 — Total debentures $ 1,686 $ — Long-term debt as of June 29, 2024 and December 30, 2023 consisted of the following (in $000's): June 29, December 30, Legacy subsidiary fixed deposits $ 2,134 $ — Legacy subsidiary loan 3,167 — Unaffiliated third-party 1,735 — Other 76 — Total notes payable, related parties 7,112 — Less current portion (3,244) — Total long-term notes payable, related parties $ 3,868 $ —

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
Long-Term Debt (Tables)	Jun. 29, 2024
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Debentures outstanding as of June 29, 2024 and December 30, 2023 consisted for the following (in $000's): June 29, December 30, Interest rate of 12%, maturity date of June 30, 2024 $ 576 $ — Interest rate of 12%, maturity date of June 30, 2025 1,110 — Total debentures $ 1,686 $ — Long-term debt as of June 29, 2024 and December 30, 2023 consisted of the following (in $000's): June 29, December 30, Legacy subsidiary fixed deposits $ 2,134 $ — Legacy subsidiary loan 3,167 — Unaffiliated third-party 1,735 — Other 76 — Total notes payable, related parties 7,112 — Less current portion (3,244) — Total long-term notes payable, related parties $ 3,868 $ —

Related Party Debt (Tables)

Related Party Debt (Tables)	6 Months Ended
Related Party Debt (Tables)	Jun. 29, 2024
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Payable to Related Parties	Long-term debt payable to related parties (see Note 20) as of June 29, 2024 and December 30, 2023 consisted of the following (in $000's): June 29, December 30, Isaac Capital Group $ — $ 707 Isaac Capital Group, 10% interest rate, matures December 31, 2024 312 — Live Ventures Incorporated, 10% interest rate, matures December 31, 2024 312 — Jon Isaac consulting agreement, 10% interest rate, matures March 4, 2026 516 Isaac Capital Group short-term demand advance, 10% interest rate 100 — Novalk Apps SAA, LLP short-term demand advance, 10% interest rate 220 — Tony Isaac short-term demand advance, 10% interest rate 62 — Total notes payable, related parties 1,522 707 Less current portion (1,006) — Total long-term notes payable, related parties $ 516 $ 707
Schedule of Debt Maturities	Twelve months ending June 29, 2025 $ 1,006 2026 516 Total future maturities of long-term debt, related parties $ 1,522

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
Stockholders' Equity (Tables)	Jun. 29, 2024
Stockholders' Equity Note [Abstract]
Schedule of all Outstanding Options	Additional information relating to all outstanding options is as follows: Options Weighted Aggregate Weighted Outstanding at December 30, 2023 114,000 $ 5.68 $ — 6.1 Outstanding at March 30, 2024 114,000 $ 5.68 $ 11 5.9 Cancelled/expired (6,000) $ 17.35 Balance at June 29, 2024 108,000 $ 5.03 $ 7 6.0 Exercisable at June 29, 2024 108,000 $ 5.03 $ 7 6.0

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
Earnings Per Share (Tables)	Jun. 29, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share	The following table presents the computation of basic and diluted net income (loss) per share (in $000’s, except share and per–share data): For the Thirteen Weeks Ended For the Twenty-Six Weeks Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Continuing Operations Basic Net income (loss) from continuing operations $ 589 $ 79 $ (1,555) $ (583) Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Basic income (loss) per share from continuing operations $ 0.07 $ 0.02 $ (0.18) $ (0.17) Diluted Net income (loss) from continuing operations $ 589 $ 79 $ (1,555) $ (583) Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Diluted income (loss) per share from continuing operations $ 0.07 $ 0.02 $ (0.18) $ (0.17) Discontinued Operations Basic Net income from discontinued operations $ — $ 44 $ — $ 10,790 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Basic income per share from discontinued operations $ — $ 0.01 $ — $ 3.14 Diluted Net income from discontinued operations $ — $ 44 $ — $ 10,790 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Diluted income per share from discontinued operations $ — $ 0.01 $ — $ 3.14 Total Basic Net income $ 589 $ 123 $ (1,555) $ 10,207 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Basic income per share $ 0.07 $ 0.03 $ (0.18) $ 2.97 Diluted Net income $ 589 $ 123 $ (1,555) $ 10,207 Weighted average common shares outstanding 8,404,102 3,665,887 8,426,349 3,432,374 Diluted income per share $ 0.07 $ 0.03 $ (0.18) $ 2.97

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
Segment Information (Tables)	Jun. 29, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	The following tables present our segment information for the 13 and 26 weeks ended June 29, 2024 and July 1, 2023 (in $000’s): Thirteen Weeks Ended Twenty-Six Weeks Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Revenues Biotechnology $ — $ — $ — $ — Fintech 2,169 — 2,169 — Discontinued operations — — — 3,795 Total Revenues $ 2,169 $ — $ 2,169 $ 3,795 Gross profit Biotechnology $ — $ — $ — $ — Fintech 1,098 — 1,098 — Discontinued operations — — — (197) Total Gross profit $ 1,098 $ — $ 1,098 $ (197) Operating income (loss) Biotechnology $ (3,177) $ (1,060) $ (4,983) $ (2,159) Fintech 261 — 261 — Discontinued operations — — — 14,159 Total Operating income (loss) $ (2,916) $ (1,060) $ (4,722) $ 12,000 Depreciation and amortization Biotechnology $ — $ 362 $ — $ 726 Fintech 179 — 179 — Discontinued operations — — — 96 Total Depreciation and amortization $ 179 $ 362 $ 179 $ 822 Interest (income) expense, net Biotechnology $ (161) $ (365) $ 91 $ (840) Fintech 157 — 157 — Discontinued operations — — — 181 Total Interest expense, net $ (4) $ (365) $ 248 $ (659) Net income (loss) before income taxes Biotechnology $ (3,112) $ 62 $ (5,331) $ (827) Fintech 850 — 850 — Discontinued operations — 1 — 13,976 Total Net income before income taxes $ (2,262) $ 63 $ (4,481) $ 13,149

Background (Details)

Background (Details) $ in Thousands	3 Months Ended		6 Months Ended
Background (Details) $ in Thousands	Jun. 29, 2024 USD ($)	Jul. 01, 2023 USD ($)	Jun. 29, 2024 USD ($) segment	Jul. 01, 2023 USD ($)	Mar. 30, 2024 USD ($)	Dec. 30, 2023 USD ($)	Apr. 01, 2023 USD ($)	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments \| segment			3
Potential market exclusivity period (in years)			7 years
Net loss from continuing operations	$ (589)	$ (79)	$ 1,555	$ 583
Current assets	30,885		30,885			$ 346
Current liabilities	42,511		42,511			5,905
Net negative working capital	11,600		11,600
Cash used in operating activities			464
Stockholders' equity	$ 22,930	$ 13,688	$ 22,930	$ 13,688	$ 3,773	$ (3,308)	$ 13,560	$ 2,307

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Accounting Policies [Abstract]
Digital assets receivable	$ 22,477	$ 0
Digital assets payable	$ 28,241	$ 0

Mergers and Acquisitions - Addi

Mergers and Acquisitions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended	6 Months Ended
	May 15, 2024	Jan. 24, 2024	Dec. 28, 2022	Mar. 30, 2024	Jun. 29, 2024	Jun. 29, 2024	Jul. 01, 2023	May 09, 2024	Dec. 30, 2023
Business Acquisition [Line Items]
Goodwill					$ 7,724	$ 7,724			$ 0
Non-cash fair value adjustment of deferred tax liabilities						2,927	$ 0
Alt 5 Sigma, Inc.
Business Acquisition [Line Items]
Number of shares issued or issuable (in shares)	1,799,100
Percentage of shares acquired	19.90%
Share price (in usd per share)								$ 4.14
Goodwill	$ 3,849
Goodwill expected to be deductible for tax purposes	0
Non-cash fair value adjustment of deferred tax liabilities					$ 3,900
Fair value of convertible tranche	$ 16,000
Alt 5 Sigma, Inc. \| Series B preferred stock
Business Acquisition [Line Items]
Number of shares issued or issuable (in shares)	34,207
Fair value of convertible tranche	$ 8,552
Alt 5 Sigma, Inc. \| Series M Preferred
Business Acquisition [Line Items]
Number of shares issued or issuable (in shares)	3,200
Soin Therapeutics LLC
Business Acquisition [Line Items]
Cash payment tendered				$ 100
Soin Therapeutics LLC \| Soin Agreement Convertible Tranche One
Business Acquisition [Line Items]
Fair value of convertible tranche		$ 3,000	$ 2,700
Soin Therapeutics LLC \| Soin Agreement Convertible Tranche Two
Business Acquisition [Line Items]
Fair value of convertible tranche		10,000	8,000
Soin Therapeutics LLC \| Soin Agreement Convertible Tranche Three
Business Acquisition [Line Items]
Fair value of convertible tranche			$ 3,900			$ 17,000
Soin Therapeutics LLC \| Business Acquisition, Consideration, Tranche One
Business Acquisition [Line Items]
Tranche payments due				100
Soin Therapeutics LLC \| Business Acquisition, Consideration, Tranche Two
Business Acquisition [Line Items]
Tranche payments due				$ 2,800
Soin Therapeutics LLC \| Series S Convertible Preferred Stock
Business Acquisition [Line Items]
Fair value of convertible tranche		$ 3,000

Mergers and Acquisitions - Sche

Mergers and Acquisitions - Schedule of Fair Value Adjustments for Shares of Series B and Series M Preferred Stock (Details) - Alt 5 Sigma, Inc. $ in Thousands	May 15, 2024 USD ($)
Business Combination Segment Allocation [Line Items]
Fair value of convertible tranche	$ 16,000
Total purchase price	16,000
Common stock
Business Combination Segment Allocation [Line Items]
Fair value of convertible tranche	7,448
Series B preferred stock
Business Combination Segment Allocation [Line Items]
Fair value of convertible tranche	$ 8,552

Mergers and Acquisitions - Sc_2

Mergers and Acquisitions - Schedule of Purchase Price Allocation of Purchase for Alt-5 to Identifiable Assets, Liabilities Assumed and Goodwill (Details) - USD ($) $ in Thousands	May 15, 2024	Jun. 29, 2024	Dec. 30, 2023
Business Combination Segment Allocation [Line Items]
Total goodwill		$ 7,724	$ 0
Alt 5 Sigma, Inc.
Business Combination Segment Allocation [Line Items]
Total purchase price	$ 16,000
Accounts payable	267
Digital assets payable	16,763
Debt	7,613
Total liabilities assumed	24,643
Total consideration	40,643
Cash	5,853
Accounts receivable	2,917
Digital assets receivable	9,082
Intangible assets	18,450
Other	492
Total assets acquired	36,794
Total goodwill	3,849
Alt 5 Sigma, Inc. \| Customer relationships
Business Combination Segment Allocation [Line Items]
Intangible assets	13,925
Alt 5 Sigma, Inc. \| Trade names
Business Combination Segment Allocation [Line Items]
Intangible assets	2,675
Alt 5 Sigma, Inc. \| Developed technology
Business Combination Segment Allocation [Line Items]
Intangible assets	$ 1,850

Mergers and Acquisitions - Sc_3

Mergers and Acquisitions - Schedule of Proforma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 29, 2024	Mar. 30, 2024	Jul. 01, 2023	Apr. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Business Combination Segment Allocation [Line Items]
Net revenue	$ 2,169		$ 0		$ 2,169	$ 0
Net income	$ 589	$ (2,144)	$ 123	$ 10,085	$ (1,555)	$ 10,207
Earnings per basic common share (in usd per share)	$ 0.07		$ 0.03		$ (0.18)	$ 2.97
Earnings per basic diluted share (in usd per share)	$ 0.07		$ 0.03		$ (0.18)	$ 2.97
Adjustments
Business Combination Segment Allocation [Line Items]
Net income	$ (269)		$ (537)		$ (806)	$ (1,074)
Proforma
Business Combination Segment Allocation [Line Items]
Net revenue	2,862		2,021		5,087	3,254
Net income	$ 526		$ 743		$ (2,290)	$ 10,525
Earnings per basic common share (in usd per share)	$ 0.06		$ 0.20		$ (0.27)	$ 3.07
Earnings per basic diluted share (in usd per share)	$ 0.06		$ 0.20		$ (0.27)	$ 3.07
Alt 5 Sigma, Inc.
Business Combination Segment Allocation [Line Items]
Business acquisition, proforma revenue	$ 693		$ 2,021		$ 2,918	$ 3,254
Business acquisition, proforma net income	$ 206		$ 1,157		$ 71	$ 1,392

Discontinued Operations - Sched

Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Operating expenses from discontinued operations:
Gain on sale of ARCA	$ 0	$ (1)	$ 0	$ (13,976)
Discontinued Operations \| ARCA And Subsidiaries \| Recycling Segment
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Revenues	0	0	0	3,795
Cost of revenues	0	0	0	3,992
Gross profit	0	0	0	(197)
Operating expenses from discontinued operations:
Selling, general and administrative expenses	0	0	0	1,468
Gain on sale of ARCA	0	0	0	(15,824)
Total operating expenses from discontinued operations	0	0	0	(14,356)
Operating income from discontinued operations	0	0	0	14,159
Other income (expense) from discontinued operations
Interest expense, net	0	0	0	(181)
Other income expense, net	0	1	0	(2)
Total other income (loss), net	0	1	0	(183)
Income before provision for income taxes from discontinued operations	0	1	0	13,976
Income tax provision (benefit)	0	(43)	0	3,186
Net income from discontinued operations	$ 0	$ 44	$ 0	$ 10,790

Discontinued Operations - Sch_2

Discontinued Operations - Schedule of Discontinued Operations in Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
DISCONTINUED OPERATING ACTIVITIES:
Net income from discontinued operations	$ 0	$ 44	$ 0	$ 10,790
Depreciation and amortization			1,300	727
Changes in assets and liabilities:
Accounts receivable			1,730	342
Net cash provided by operating activities from discontinued operations			0	2,320
DISCONTINUED INVESTING ACTIVITIES:
Net cash used in investing activities from discontinued operations			0	(156)
DISCONTINUED FINANCING ACTIVITIES:
Proceeds from note payable			577	0
Payments on notes payable			251	274
Net cash used in financing activities from discontinued operations			0	(2,212)
Effect of changes in exchange rate on cash and cash equivalents			(807)	17
DECREASE IN CASH AND CASH EQUIVALENTS			5,759	54
CASH AND CASH EQUIVALENTS, beginning of period			5	115
CASH AND CASH EQUIVALENTS, end of period	5,764	169	5,764	169
Discontinued Operations \| ARCA And Subsidiaries \| Recycling Segment
DISCONTINUED OPERATING ACTIVITIES:
Net income from discontinued operations			0	10,790
Depreciation and amortization			0	96
Amortization of debt issuance costs			0	11
Amortization of right-of-use assets			0	53
Change in deferred taxes			0	3,185
Gain on sale of ARCA, net of cash			0	(15,967)
Gain on sale of GeoTraq			0	0
Changes in assets and liabilities:
Accounts receivable			0	2,932
Inventories			0	299
Prepaid expenses and other current assets			0	55
Accounts payable and accrued expenses			0	866
Net cash provided by operating activities from discontinued operations			0	2,320
DISCONTINUED INVESTING ACTIVITIES:
Purchases of property and equipment			0	(123)
Purchase of intangible assets			0	(33)
Net cash used in investing activities from discontinued operations			0	(156)
DISCONTINUED FINANCING ACTIVITIES:
Proceeds from note payable			0	5,162
Payment on related party note			0	(38)
Proceeds from issuance of short-term notes payable			0	(7,291)
Payments on notes payable			0	45
Net cash used in financing activities from discontinued operations			0	(2,212)
Effect of changes in exchange rate on cash and cash equivalents			0	(5)
DECREASE IN CASH AND CASH EQUIVALENTS			0	(53)
CASH AND CASH EQUIVALENTS, beginning of period			0	53
CASH AND CASH EQUIVALENTS, end of period	$ 0	$ 0	$ 0	$ 0

Trade and other receivables (De

Trade and other receivables (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Receivables [Abstract]
Trade receivables	$ 865	$ 0
Interest receivable - SPYR	69	266
Other receivables	50	0
Trade and other receivables, net	$ 984	$ 266

Prepaids and other current as_3

Prepaids and other current assets (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting agreements	$ 1,145	$ 3
Prepaid insurance	3	72
Prepaid other	512	0
Total prepaid expenses and other current assets	$ 1,660	$ 75

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Property Plant And Equipment [Line Items]
Property and equipment, net	$ 1,170	$ 0
Projects under construction
Property Plant And Equipment [Line Items]
Property and equipment, net	$ 1,170	$ 0

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 0

Leases - Schedule of Company's

Leases - Schedule of Company's Right of Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Leases [Abstract]
Right of use asset - operating leases	$ 186	$ 0
Current - operating	59	0
Long term - operating	$ 127	$ 0

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	6 Months Ended
Leases - Additional Information (Details) - USD ($)	Jun. 29, 2024	Jul. 01, 2023
Leases [Abstract]
Weighted average lease term (in years)	2 years 8 months 12 days
Weighted average discount rate (as a percent)	11.50%
Cash payment for operating leases	$ 39,000	$ 0
Right of use assets and liabilities upon commencement of operating leases	$ 186,000

Leases - Schedule of Present Va

Leases - Schedule of Present Value of Future Lease Payments of Operating Leases (Details) $ in Thousands	Jun. 29, 2024 USD ($)
Leases [Abstract]
2025	$ 77
2026	77
2027	65
Total	219
Less implied interest	(33)
Present value of payments	$ 186

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) $ in Thousands	Jun. 29, 2024 USD ($) patent	Dec. 30, 2023 USD ($) patent
Finite Lived Intangible Assets [Line Items]
Intangible assets	$ 37,747	$ 19,297
Less accumulated amortization	(2,751)	(1,451)
Total intangible assets	$ 34,996	$ 17,846
Number of pending patents \| patent	2	2
Number of approved patents \| patent	1	1
Soin Intangibles
Finite Lived Intangible Assets [Line Items]
Intangible assets	$ 19,293	$ 19,293
Customer relationships
Finite Lived Intangible Assets [Line Items]
Intangible assets	13,925	0
Trade names
Finite Lived Intangible Assets [Line Items]
Intangible assets	2,675	0
Developed technology
Finite Lived Intangible Assets [Line Items]
Intangible assets	1,850	0
Patents and domains
Finite Lived Intangible Assets [Line Items]
Intangible assets	$ 4	$ 4

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 660	$ 363	$ 1,300	$ 726

Marketable Securities (Details)

Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Mar. 30, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Marketable Securities, Value [Roll Forward]
Beginning balance	$ 180	$ 286		$ 286
Securities received	434	84
Mark-to-market	(180)	(190)	$ 0	(370)	$ (247)
Ending balance	$ 434	$ 180		$ 434
Series G Convertible Preferred Shares
Marketable Securities, Shares [Roll Forward]
Beginning balance (in shares)	17,693	9,224		9,224
Securities received (in shares)	25,407	8,469
Ending balance (in shares)	43,100	17,693		43,100
Common Shares Equivalent
Marketable Securities, Shares [Roll Forward]
Beginning balance (in shares)	1,799,342,000	952,442,000		952,442,000
Securities received (in shares)	25,407,000,000	846,900,000
Ending balance (in shares)	27,206,342,000	1,799,342,000		27,206,342,000

Deposits and Other Assets (Deta

Deposits and Other Assets (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other	$ 0	$ 9
Total deposits and other assets	$ 0	$ 9

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Payables and Accruals [Abstract]
Compensation and benefits	$ 46	$ 37
Accrued guarantees	1,209	3,049
Accrued Legal	397	0
Accrued taxes	110	102
Accrued litigation settlement	650	397
Other	26	48
Total accrued expenses	$ 2,438	$ 3,633

Debentures - Schedule of Debent

Debentures - Schedule of Debentures Outstanding (Details) - Debentures - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Total debentures	$ 1,686	$ 0
12% Debentures Maturing June 30, 2024
Debt Instrument [Line Items]
Debt interest rate (as a percent)		12%
Total debentures	$ 576	$ 0
12% Debentures Maturing June 30, 2025
Debt Instrument [Line Items]
Debt interest rate (as a percent)	12%
Total debentures	$ 1,110	$ 0

Debentures - Additional Informa

Debentures - Additional Information (Details) - Debentures - debenture	12 Months Ended
	Sep. 30, 2019	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Number of debentures issued	39
12% Debentures Maturing June 30, 2025
Debt Instrument [Line Items]
Debt interest rate (as a percent)		12%
12% Debentures Maturing June 30, 2024
Debt Instrument [Line Items]
Debt interest rate (as a percent)			12%

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt (Details) - Long-Term Debt [Member] - Related Party - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Total notes payable, related parties	$ 7,112	$ 0
Less current portion	(3,244)	0
Total long-term notes payable, related parties	3,868	0
Legacy subsidiary fixed deposits
Debt Instrument [Line Items]
Total notes payable, related parties	2,134	0
Legacy subsidiary loan
Debt Instrument [Line Items]
Total notes payable, related parties	3,167	0
Unaffiliated third-party
Debt Instrument [Line Items]
Total notes payable, related parties	1,735	0
Other
Debt Instrument [Line Items]
Total notes payable, related parties	$ 76	$ 0

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - Related Party - USD ($) $ / shares in Units, shares in Thousands	Apr. 12, 2024	Apr. 10, 2024	Mar. 25, 2024	Mar. 22, 2024	Jun. 29, 2024	Apr. 30, 2024	Feb. 07, 2024	Dec. 30, 2023
Long-Term Debt [Member]
Debt Instrument [Line Items]
Outstanding aggregate obligations					$ 7,112,000			$ 0
Legacy subsidiary fixed deposits \| Long-Term Debt [Member]
Debt Instrument [Line Items]
Debt face amount						$ 2,400,000
Debt interest rate (as a percent)					12%
Outstanding aggregate obligations					$ 2,134,000			0
Legacy subsidiary loan \| Long-Term Debt [Member]
Debt Instrument [Line Items]
Debt interest rate (as a percent)					15%
Outstanding aggregate obligations					$ 3,167,000			$ 0
Isaac Capital Group Promissory Note \| Promissory Note \| Notes Payable With Live Ventures and ICG
Debt Instrument [Line Items]
Debt face amount							$ 1,200,000
Conversion price (in usd per share)							$ 0.61
Debt conversion, converted amount	$ 60,900		$ 183,000
Debt conversion, converted (in shares)	100		300
Principal outstanding balance					952,000
Live Note \| Promissory Note \| Notes Payable With Live Ventures and ICG
Debt Instrument [Line Items]
Debt face amount							$ 1,000,000
Conversion price (in usd per share)							$ 0.61
Debt conversion, converted amount		$ 60,900		$ 183,000
Debt conversion, converted (in shares)		100		300
Principal outstanding balance					$ 782,000

Related Party Debt - Schedule o

Related Party Debt - Schedule of Long-Term Debt Payable to Related Parties (Details) - Related Party - USD ($) $ in Thousands	Jun. 29, 2024	Jun. 03, 2024	May 28, 2024	Apr. 18, 2024	Mar. 04, 2024	Feb. 07, 2024	Dec. 30, 2023	Jul. 01, 2023
Short Term Advances \| Novalk Apps SAA, LLP
Debt Instrument [Line Items]
Debt interest rate (as a percent)	10%	10%	10%				10%
Short Term Advances \| Mr. Tony Isaac
Debt Instrument [Line Items]
Debt interest rate (as a percent)	10%	10%					10%
Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	$ 1,522						$ 707
Less current portion	(1,006)						0
Total long-term notes payable, related parties	516						707
Isaac Capital Group \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	0						707
Note Payable To Isaac Capital Group \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	312						0
Note Payable To Isaac Capital Group \| Notes Payable \| Notes Payable With Live Ventures and ICG
Debt Instrument [Line Items]
Debt interest rate (as a percent)						10%
Note Payable To Live Venture Incorporated \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	$ 312						$ 0
Debt interest rate (as a percent)								10%
10% Convertible Promissory Note \| Notes Payable \| Isaac Consulting Agreement
Debt Instrument [Line Items]
Debt interest rate (as a percent)	10%				10%		10%
Note Payable To Jon Isaac Consulting Agreement \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	$ 516
Isaac Capital Group Short-Term Demand Advance \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	100						$ 0
Isaac Capital Group Short-Term Demand Advance \| Notes Payable \| Isaac Capital Group Promissory Note
Debt Instrument [Line Items]
Total notes payable, related parties	$ 100
Debt interest rate (as a percent)	10%			10%			10%
Novalk Apps SAA, LLP \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	$ 220						$ 0
Tony Isaac Short Term Demand Advance \| Notes Payable
Debt Instrument [Line Items]
Total notes payable, related parties	$ 62						$ 0

Related Party Debt - Schedule_2

Related Party Debt - Schedule of Future Maturities of Long Term Debt (Details) - Notes Payable Related Parties - Related Party $ in Thousands	Jun. 29, 2024 USD ($)
Debt Instrument [Line Items]
2025	$ 1,006
2026	516
Total notes payable, related parties	$ 1,522

Related Party Debt - Additional

Related Party Debt - Additional Information (Details) - Related Party - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jun. 06, 2024	Jun. 03, 2024	May 28, 2024	Apr. 18, 2024	Mar. 25, 2024	Mar. 22, 2024	Mar. 04, 2024	Jun. 29, 2024	Feb. 07, 2024	Dec. 30, 2023
Promissory note
Debt Instrument [Line Items]
Principle outstanding balance								$ 1,522		$ 707
Promissory note \| Isaac Capital Group Short-Term Demand Advance
Debt Instrument [Line Items]
Principle outstanding balance								100		$ 0
Isaac Capital Group Promissory Note \| Promissory note \| Isaac Capital Group Promissory Note
Debt Instrument [Line Items]
Conversion price (in usd per share)									$ 0.61
Debt face amount									$ 1,200
Debt conversion, converted amount					$ 183
Principle outstanding balance								312
Isaac Capital Group Promissory Note \| Promissory note \| Isaac Capital Group Promissory Note \| Equity Unit Purchase Agreements
Debt Instrument [Line Items]
Debt conversion, converted (in shares)					300
Isaac Capital Group Promissory Note \| Promissory note \| Isaac Capital Group Short-Term Demand Advance
Debt Instrument [Line Items]
Principle outstanding balance								$ 100
Proceeds from short-term demand advances				$ 100
Debt interest rate (as a percent)				10%				10%		10%
Live Venture Incorporated \| Promissory note \| Live Note
Debt Instrument [Line Items]
Conversion price (in usd per share)									$ 0.61
Debt face amount									$ 1,000
Debt conversion, converted amount						$ 183
Principle outstanding balance								$ 312
Live Venture Incorporated \| Promissory note \| Live Note \| Equity Unit Purchase Agreements
Debt Instrument [Line Items]
Debt conversion, converted (in shares)						300
Isaac Consulting Agreement
Debt Instrument [Line Items]
Term of consulting agreement (in years)	1 year	6 months
Isaac Consulting Agreement \| Promissory note \| 10% Convertible Promissory Note
Debt Instrument [Line Items]
Debt face amount							$ 500
Debt interest rate (as a percent)							10%	10%		10%
Debt instrument term (in years)							2 years
Mr. Jon Isaac \| Isaac Consulting Agreement
Debt Instrument [Line Items]
Principle outstanding balance								$ 516
Term of consulting agreement (in years)							2 years
Per share value of the restricted shares issued (in usd per share)							$ 1.16
Mr. Jon Isaac \| Isaac Consulting Agreement \| 10% Convertible Promissory Note
Debt Instrument [Line Items]
Term of consulting agreement (in years)							2 years
Novalk Apps SAA, LLP \| Short Term Advances
Debt Instrument [Line Items]
Proceeds from short-term demand advances		$ 100	$ 120
Debt interest rate (as a percent)		10%	10%					10%		10%
Principal amount outstanding of short term advances								$ 220
Mr. Tony Isaac \| Short Term Advances
Debt Instrument [Line Items]
Proceeds from short-term demand advances		$ 62
Debt interest rate (as a percent)		10%						10%		10%
Principal amount outstanding of short term advances								$ 62

Commitments and Contingencies (

Commitments and Contingencies (Details)

6 Months Ended

May 28, 2024 USD ($) payment

Apr. 10, 2024 USD ($) $ / shares

Sep. 30, 2023 shares

Sep. 01, 2023 shares

Jun. 04, 2023 USD ($)

Jun. 01, 2023 shares

Mar. 17, 2023 shares

Oct. 19, 2022 USD ($)

Jun. 01, 2021 USD ($) installment

Apr. 09, 2021 USD ($)

Feb. 01, 2021 USD ($)

Jun. 29, 2024 USD ($) tranche

Dec. 30, 2023 USD ($) guarantee

Aug. 02, 2021 officer

Jan. 02, 2021 USD ($)

Dec. 30, 2017 landlord

SEC Complaint

Loss Contingencies [Line Items]

Number of executive officers named in complaint | officer

Penalty awarded

$ 250,000

Number of quarterly payments | payment

Quarterly payment amounts

$ 62,500

Skybridge Litigation | Promissory Note

Loss Contingencies [Line Items]

Debt face amount

$ 147,956.47

Debt interest rate (as a percent)

10%

Conversion price (in usd per share) | $ / shares

$ 2.60

Skybridge Litigation | SA

Loss Contingencies [Line Items]

Damages assessed plus interest and attorney fees

$ 433,920.03

$ 715,000

Skybridge Litigation | SA | Interest, Fees, And Costs And Attorneys' Fees

Loss Contingencies [Line Items]

Damages assessed plus interest and attorney fees

$ 475,000

Skybridge Litigation | SA | Statutory Interest

Loss Contingencies [Line Items]

Damages assessed plus interest and attorney fees

$ 422,000

Skybridge Litigation | SA | Legal Fees

Loss Contingencies [Line Items]

Damages assessed plus interest and attorney fees

$ 18,123.5

GeoTraq Litigation

Loss Contingencies [Line Items]

Number of quarterly installments | installment

GeoTraq Litigation | Common Stock

Loss Contingencies [Line Items]

Conversion of stock, shares issued (in shares) | shares

289,421

153,941

GeoTraq Litigation | Series A-1 Preferred

Loss Contingencies [Line Items]

Conversion of stock, shares converted (in shares) | shares

14,471

7,697

5,185

Shares returned to the company for cancellation (in shares) | shares

1,505

GeoTraq Litigation | GeoTraq Inc.

Loss Contingencies [Line Items]

Damages sought value

$ 1,950,000

Payments for legal settlements

$ 170,000

$ 250,000

Percent of prepayment tender restrictions

50%

Conversion of stock, shares issued (in shares) | shares

103,707

Alixpartners, LLC Litigation | Alixpartners, LLC

Loss Contingencies [Line Items]

Penalty awarded

125,000

Damages assessed plus interest and attorney fees

$ 450,000

Damages sought value

$ 345,000

Number of tranches | tranche

Main / 270, LLC Litigation | Trustees Main/270, LLC

Loss Contingencies [Line Items]

Damages sought value

$ 90,000

Main / 270, LLC Litigation | Trustees Main/270, LLC | Appliance Smart, Inc.

Loss Contingencies [Line Items]

Damages sought value

1,420,000

Westerville Square Litigation | Westerville Square

Loss Contingencies [Line Items]

Damages sought value

$ 120,000

Payments for legal settlements

$ 110,000

Other Commitments And Litigation Cases

Loss Contingencies [Line Items]

Number of landlords originally purported to be covered under company's guarantee or commitment | landlord

Number of landlords company is no longer liable for | guarantee

Other Commitments And Litigation Cases | Appliance Smart, Inc.

Loss Contingencies [Line Items]

Amount owed by company

$ 767,000

Future lease payments

$ 637,000

Accrued liabilities

$ 130,000

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details)

3 Months Ended

6 Months Ended

Jun. 06, 2024 shares

Jun. 03, 2024 shares

May 15, 2024 shares

May 01, 2024 USD ($) investor $ / shares shares

Apr. 12, 2024 USD ($) shares

Apr. 10, 2024 USD ($) shares

Mar. 25, 2024 USD ($) shares

Mar. 22, 2024 USD ($) shares

Mar. 04, 2024 $ / shares shares

Feb. 23, 2024 USD ($) investor $ / shares shares

Oct. 09, 2023 USD ($) $ / shares shares

Aug. 18, 2023 $ / shares shares

Jun. 29, 2024 USD ($) $ / shares shares

Mar. 30, 2024 USD ($) shares

Jul. 01, 2023 shares

Apr. 01, 2023 USD ($)

Jun. 29, 2024 $ / shares shares

May 09, 2024 $ / shares

Dec. 30, 2023 $ / shares shares

Shareholders Equity [Line Items]

Common stock, shares authorized (in shares)

200,000,000

Common stock issued for consulting agreement (in shares)

Common Stock, par value (in usd per share) | $ / shares

$ 0.001

Common stock, issued shares (in shares)

12,589,015

4,957,647

Common stock, outstanding shares (in shares)

12,589,015

4,957,647

Common stock issued for equity financing | $

$ 342,000

$ 627,000

$ 369,000

Alt 5 Sigma, Inc.

Shareholders Equity [Line Items]

Share price (in usd per share) | $ / shares

$ 4.14

Company tendered (in shares)

1,799,100

Isaac Capital Group Promissory Note | Related Party | Isaac Capital Group Promissory Note | Promissory Note

Shareholders Equity [Line Items]

Debt conversion, converted amount | $

$ 60,900

$ 183,000

North York LTD | Related Party

Shareholders Equity [Line Items]

Sale of stock, number of shares issued in transaction (in shares)

125,000

Warrant exercise price (in usd per share) | $ / shares

$ 1.25

Warrants and rights outstanding, term (in years)

3 years

North York LTD | Related Party | Series V Convertible Preferred Stock

Shareholders Equity [Line Items]

Sale of stock, number of shares issued in transaction (in shares)

5,000

Isaac Consulting Agreement | Related Party

Shareholders Equity [Line Items]

Common stock issued for consulting agreement (in shares)

150,000

Term of consulting agreement (in years)

1 year

6 months

Restricted shares issued (in shares)

47,923

Isaac Consulting Agreement | Related Party | Mr. Jon Isaac

Shareholders Equity [Line Items]

Term of consulting agreement (in years)

2 years

Restricted shares issued (in shares)

200,000

232,000

2023 Plan | Related Party

Shareholders Equity [Line Items]

Common stock issued for consulting agreement (in shares)

295,000

Common stock issued (in shares)

295,000

Common stock issued for equity financing | $

$ 1,200,000

Restricted Stock Units (RSUs) | North York LTD | Related Party | Common Stock

Shareholders Equity [Line Items]

Sale of stock, number of shares issued in transaction (in shares)

300,000

Restricted Stock Units (RSUs) | 2023 Plan

Shareholders Equity [Line Items]

Common stock issued for consulting agreement (in shares)

908,852

Common stock issued for RSU's granted (in shares)

908,852

Common stock issued for RSU's granted | $

$ 345,000

Share price (in usd per share) | $ / shares

$ 0.3796

Placement Agency Agreement

Shareholders Equity [Line Items]

Common stock issued for consulting agreement (in shares)

27,738

Sale of stock, number of shares issued in transaction (in shares)

418,000

Common Stock, par value (in usd per share) | $ / shares

$ 0.001

Sale of stock, price (in usd per share) | $ / shares

$ 0.8811

Placement Agency Agreement | Pre-Funded Warrants

Shareholders Equity [Line Items]

Class of warrant or right, number of securities called by warrants or rights (in shares)

481,348

Warrant exercise price (in usd per share) | $ / shares

$ 0.8801

Equity Unit Purchase Agreements | Related Party

Shareholders Equity [Line Items]

Sale of stock, number of shares issued in transaction (in shares)

79,782

408,163

Equity Unit Purchase Agreements | Isaac Capital Group Promissory Note | Related Party

Shareholders Equity [Line Items]

Sale of stock, price (in usd per share) | $ / shares

$ 3.775

$ 0.7350

Warrant exercise price (in usd per share) | $ / shares

$ 3.63

$ 0.61

Unaffiliated third-part investors | investor

Aggregate purchase price | $

$ 300,000

Sale of stock, aggregate price | $

$ 300,000

$ 600,000

Number of common shares in each unit (in shares)

Number of warrants in each unit (in shares)

Class of warrant price per share (in usd per share) | $ / shares

$ 0.125

Warrants and rights outstanding, term (in years)

3 years

Equity Unit Purchase Agreements | Isaac Capital Group Promissory Note | Related Party | Isaac Capital Group Promissory Note | Promissory Note

Shareholders Equity [Line Items]

Debt conversion, converted (in shares)

100,000

300,000

Third-Party Exchange For Brokerage Services | Related Party

Shareholders Equity [Line Items]

Sale of stock, number of shares issued in transaction (in shares)

81,632

Articles of Incorporation

Shareholders Equity [Line Items]

Common stock, shares authorized (in shares)

200,000,000

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options (Details) - USD ($)		3 Months Ended		6 Months Ended
Stockholders' Equity - Stock Options (Details) - USD ($)	Oct. 09, 2023	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Mar. 30, 2024	Dec. 30, 2023	Nov. 04, 2020	Nov. 03, 2020
Shareholders Equity [Line Items]
Common stock issued for consulting agreement (in shares)		0	0
Options outstanding (in shares)		108,000		108,000		114,000	114,000
Stock Options
Shareholders Equity [Line Items]
Share-based compensation expense		$ 1,200,000	$ 4,000,000	$ 1,500,000	$ 12,000,000
Unrecognized compensation expense, net of estimated forfeitures		$ 0		$ 0
2023 Plan
Shareholders Equity [Line Items]
Options authorized for issuance (in shares)		2,000,000		2,000,000
2023 Plan \| Restricted Stock Units (RSUs)
Shareholders Equity [Line Items]
Share-based compensation expense		$ 1,200,000		$ 1,500,000
Common stock issued for RSU's granted (in shares)	908,852	908,852
Common stock issued for consulting agreement (in shares)				908,852
2016 Plan
Shareholders Equity [Line Items]
Options authorized for issuance (in shares)								800,000	400,000
Options outstanding (in shares)		100,000		100,000			100,000
2011 Plan
Shareholders Equity [Line Items]
Options outstanding (in shares)		14,000		14,000			14,000
Share-based compensation , number of additional shares authorized (in shares)				0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of All Outstanding Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 29, 2024	Mar. 30, 2024	Dec. 30, 2023
Options Outstanding
Beginning Balance (in shares)	114,000	114,000
Cancelled/expired (in shares)	(6,000)
Ending Balance (in shares)	108,000	114,000	114,000
Exercisable (in shares)	108,000
Weighted Average Exercise Price
Beginning Balance (in usd per share)	$ 5.68	$ 5.68
Cancelled/expired (in usd per share)	17.35
Ending Balance (in usd per share)	5.03	$ 5.68	$ 5.68
Exercisable (in usd per share)	$ 5.03
Aggregate Intrinsic Value [Abstract]
Options outstanding	$ 7	$ 11	$ 0
Options exercisable	$ 7
Weighted average remaining contractual life (in years)	6 years	5 years 10 months 24 days	6 years 1 month 6 days
Weighted average remaining contractual life, exercisable (in years)	6 years

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock (Details) $ in Millions		6 Months Ended
	Dec. 28, 2022 USD ($) shares	Jun. 29, 2024 shares	Dec. 30, 2023 shares
Series A-1 Preferred
Shareholders Equity [Line Items]
Series A-1 preferred converted (in shares)		123,750
Preferred stock, outstanding shares (in shares)		69,980	193,730
Series S Convertible Preferred Stock
Shareholders Equity [Line Items]
Preferred stock, outstanding shares (in shares)		100,000	100,000
Preferred stock, conversion ratio		1
Series S Convertible Preferred Stock \| Soin Therapeutics
Shareholders Equity [Line Items]
Issuance of shares of common stock to legacy equity holders \| $	$ 30
Company tendered (in shares)	100,000

Mezzanine Equity (Details)

Mezzanine Equity (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
Mezzanine Equity (Details) - USD ($) $ in Thousands	Mar. 30, 2024	Jun. 29, 2024
Mezzanine equity [Abstract]
Reclassification of Series S stock from mezzanine equity to current liabilities		$ 2,700
Reclassification of Series S stock from mezzanine equity to permanent equity	$ 7,993	8,000
Outstanding balance in mezzanine equity		$ 3,900

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Continuing Operations
Net income (loss) from continuing operations, basic	$ 589	$ 79	$ (1,555)	$ (583)
Weighted average common shares outstanding, basic (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Basic income (loss) per share from continuing operations ( in usd per share)	$ 0.07	$ 0.02	$ (0.18)	$ (0.17)
Net income (loss) from continuing operations, diluted	$ 589	$ 79	$ (1,555)	$ (583)
Weighted average common shares outstanding, diluted (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Diluted income (loss) per share from continuing operations (in usd per share)	$ 0.07	$ 0.02	$ (0.18)	$ (0.17)
Discontinued Operations
Net income from discontinued operations, basic	$ 0	$ 44	$ 0	$ 10,790
Weighted average common shares outstanding, basic (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Basic income per share from discontinued operations, basic (in usd per share)	$ 0	$ 0.01	$ 0	$ 3.14
Net income from discontinued operations, diluted	$ 0	$ 44	$ 0	$ 10,790
Weighted average common shares outstanding, diluted (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Diluted income per share from discontinued operations, diluted (in usd per share)	$ 0	$ 0.01	$ 0	$ 3.14
Basic
Net income	$ 589	$ 123	$ (1,555)	$ 10,207
Weighted average common shares outstanding (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Basic income per share (in usd per share)	$ 0.07	$ 0.03	$ (0.18)	$ 2.97
Diluted
Net income	$ 589	$ 123	$ (1,555)	$ 10,207
Weighted average common shares outstanding (in shares)	8,404,102	3,665,887	8,426,349	3,432,374
Diluted income per share (in usd per share)	$ 0.07	$ 0.03	$ (0.18)	$ 2.97

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Details) - shares	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares excluded from earnings per share calculation (in shares)	108,000	114,000
Preferred Stock \| Series S
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares excluded from earnings per share calculation (in shares)	100,000
Preferred stock convertible into common shares (in shares)	3,000,000
Preferred Stock \| Series A-1 Preferred
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares converted (in shares)	69,980
Preferred stock convertible into common shares (in shares)	1,400,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Income Tax Contingency [Line Items]
Income tax expense (benefit)	$ (2,851)	$ (17)	$ (2,926)	$ (244)
Effective tax rate (as a percent)			65.30%	29.50%
Discontinued Operations
Income Tax Contingency [Line Items]
Income tax expense (benefit)	$ 0	$ 43	$ 0	$ 3,200

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	6 Months Ended
Segment Reporting - Additional Information (Details)	Jun. 29, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segment Information - Schedule

Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Segment Reporting Information [Line Items]
Revenues	$ 2,169	$ 0	$ 2,169	$ 0
Gross profit	1,098	0	1,098	0
Operating income (loss)	(2,916)	(1,060)	(4,722)	(2,159)
Depreciation and amortization			1,300	727
Interest (income) expense, net	(4)	(365)	248	(840)
Net income (loss) before income taxes	(2,262)	62	(4,481)	(827)
Total Net income before income taxes	589	123	(1,555)	10,207
Continuing Operations And Discontinuing Operations
Segment Reporting Information [Line Items]
Revenues	2,169	0	2,169	3,795
Gross profit	1,098	0	1,098	(197)
Operating income (loss)	(2,916)	(1,060)	(4,722)	12,000
Depreciation and amortization	179	362	179	822
Interest (income) expense, net	(4)	(365)	248	(659)
Net income (loss) before income taxes	(2,262)	63	(4,481)	13,149
Biotechnology
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Gross profit	0	0	0	0
Operating income (loss)	(3,177)	(1,060)	(4,983)	(2,159)
Depreciation and amortization	0	362	0	726
Interest (income) expense, net	(161)	(365)	91	(840)
Net income (loss) before income taxes	(3,112)	62	(5,331)	(827)
Fintech
Segment Reporting Information [Line Items]
Revenues	2,169	0	2,169	0
Gross profit	1,098	0	1,098	0
Operating income (loss)	261	0	261	0
Depreciation and amortization	179	0	179	0
Interest (income) expense, net	157	0	157	0
Net income (loss) before income taxes	850	0	850	0
Recycling Segment \| Discontinued Operations
Segment Reporting Information [Line Items]
Revenues	0	0	0	3,795
Gross profit	0	0	0	(197)
Operating income (loss)	0	0	0	14,159
Depreciation and amortization	0	0	0	96
Interest (income) expense, net	0	0	0	181
Net income (loss) before income taxes	$ 0	$ 1	$ 0	$ 13,976

Related Parties (Details)

Related Parties (Details) - Related Party							3 Months Ended		6 Months Ended
Related Parties (Details) - Related Party	Jun. 06, 2024	Jun. 03, 2024 USD ($) shares	May 28, 2024 USD ($)	Apr. 18, 2024 USD ($)	Mar. 04, 2024 USD ($) trading_day insurance_policy $ / shares shares	Feb. 07, 2024 USD ($) $ / shares	Jun. 29, 2024 USD ($) ft²	Jul. 01, 2023 USD ($)	Jun. 29, 2024 USD ($) ft² shares	Jul. 01, 2023 USD ($)	Dec. 30, 2023 USD ($)
Promissory note
Related Party Transaction [Line Items]
Principal outstanding balance							$ 1,522,000		$ 1,522,000		$ 707,000
Isaac Capital Group Short-Term Demand Advance \| Promissory note
Related Party Transaction [Line Items]
Principal outstanding balance							100,000		100,000		$ 0
Notes Payable With Live Ventures and ICG \| Live Ventures and ICG Notes \| Promissory Note
Related Party Transaction [Line Items]
Debt face amount						$ 300,000
Monthly installment						$ 100,000
Conversion price (in usd per share) \| $ / shares						$ 0.61
Principal outstanding balance							$ 312,000		$ 312,000
Isaac Consulting Agreement
Related Party Transaction [Line Items]
Term of consulting agreement (in years)	1 year	6 months
Restricted shares issued (in shares) \| shares		47,923
Isaac Consulting Agreement \| 10% Convertible Promissory Note \| Promissory note
Related Party Transaction [Line Items]
Debt face amount					$ 500,000
Debt interest rate (as a percent)					10%		10%		10%		10%
Isaac Capital Group Promissory Note \| Isaac Capital Group Short-Term Demand Advance \| Promissory note
Related Party Transaction [Line Items]
Debt interest rate (as a percent)				10%			10%		10%		10%
Principal outstanding balance							$ 100,000		$ 100,000
Proceeds from short-term demand advances				$ 100,000
Live Ventures Incorporated
Related Party Transaction [Line Items]
Shared expenses with another company							$ 0	$ 55,000	$ 0	$ 87,000
Rented office space (in sqft) \| ft²							9,900		9,900
Operating lease expense							$ 34,000	$ 67,000	$ 109,000	$ 103,000
Mr. Jon Isaac \| Isaac Consulting Agreement
Related Party Transaction [Line Items]
Principal outstanding balance							$ 516,000		$ 516,000
Term of consulting agreement (in years)					2 years
Universal life insurance policies assigned \| insurance_policy					2
Contingently tendered funds in counsel's trust account					$ 220,000
Restricted shares issued (in shares) \| shares					200,000				232,000
Number of trading days prior to court approval (in days) \| trading_day					5
Term of promissory note issued (in years)					2 years
Per share value of the restricted shares issued (in usd per share) \| $ / shares					$ 1.16
Mr. Jon Isaac \| Isaac Consulting Agreement \| Universal Life Insurance Policy, Policy One
Related Party Transaction [Line Items]
Cash surrender value of life insurance					$ 3,854
Mr. Jon Isaac \| Isaac Consulting Agreement \| Universal Life Insurance Policy, Policy Two
Related Party Transaction [Line Items]
Cash surrender value of life insurance					$ 468
Mr. Jon Isaac \| Isaac Consulting Agreement \| 10% Convertible Promissory Note
Related Party Transaction [Line Items]
Term of consulting agreement (in years)					2 years
Novalk Apps SAA, LLP \| Short Term Advances
Related Party Transaction [Line Items]
Debt interest rate (as a percent)		10%	10%				10%		10%		10%
Proceeds from short-term demand advances		$ 100,000	$ 120,000
Principal amount outstanding of short term advances							$ 220,000		$ 220,000
Mr. Tony Isaac \| Short Term Advances
Related Party Transaction [Line Items]
Debt interest rate (as a percent)		10%					10%		10%		10%
Proceeds from short-term demand advances		$ 62,000
Principal amount outstanding of short term advances							$ 62,000		$ 62,000